Genome-wide antibiotic resistance and virulence profiling of Pseudomonas Aeruginosa isolated from clinical samples in Lebanon. (c2017) by Harb, Cynthia P.
LEBANESE AMERICAN UNIVERSITY 
Genome-wide Antibiotic Resistance and Virulence Profiling of Pseudomonas 
aeruginosa Isolated from Clinical Samples in Lebanon 
By 
Cynthia P. Harb 
A thesis 
Submitted in partial fulfillment of the requirements 
for the degree of Master of Science in Molecular Biology 
School of Arts and Sciences 
April 2017

.. LAU 
~ ~\~~\ ~t:J.-1 
- 'fa. - . . 
Lebanese American University 
THESIS COPYRIGHT RELEASE FORM 
LEBANESE AMERICAN UNIVERSITY NON-EXCLUSIVE DISTRIBUTION LICENSE 
By signing and submitting this license, you (the author(s) or copyright owner) grants the Lebanese American University (LAU) the 
non-exclusive right to reproduce, translate (as defined below), and/or distribute your submission (including the abstract) worldwide 
in print and electronic formats and in any medium, including but not limited to audio or video. You agree that LAU may, without 
changing the content, translate the submission to any medium or format for the purpose of preservation. You also agree that 
LAU may keep more than one copy of this submission for purposes of security, backup and preservation. You represent that the 
submission is your original work, and that you have the right to grant the rights contained in this license. You also represent that 
your submission does not, to the best of your knowledge, infringe upon anyone's copyright. If the submission contains material for 
which you do not hold copyright, you represent that you have obtained the unrestricted permission of the copyright owner to grant 
LAU the rights required by this license, and that such third-party owned material is clearly identified and acknowledged within the 
text or content of the submission. IF THE SUBMISSION IS BASED UPON WORK THAT HAS BEEN SPONSORED OR SUPPORTED BY 
AN AGENCY OR ORGANIZATION OTHER THAN LAU, YOU REPRESENT THAT YOU HAVE FULFILLED ANY RIGHT OF REVIEW OR OTHER 
OBLIGATIONS REQUIRED BY SUCH CONTRACT OR AGREEMENT. LAU will clearly identify your name(s) as the author(s) or owner(s) 
of the submission, and will not make any alteration, other than as allowed by this license, to your submission. 
Name: C 'J~o.. \-\ru-\o 
Signature:     
Date: a 5 Joy) d0 /""± 
lDILAU 
z::_s; :'ii ~\:.....'..Jl \ ~GI 
- 'fi..A - • • 
Lebanese American University 
PLAGIARISM POLICY COMPLIANCE STATEMENT 
I certify that: 
1. I have read and understood LAU's Plagiarism Policy. 
2. I understand that failure to comply with th is Policy can lead to academic and disciplinary actions against me. 
3 . This work is substantially my own, and to the extentthat any part of this work is not my own I have indicated that by acknowledging 
its sources. 
Name: ~$'.\ \-\ns-'c 
s;gnatureo 
Date: ;;), 5/ dJ I ;20\3-1 I 
v 
 
 
 
 
 
 
 
 
 
 
To my loving parents, I dedicate this work… 
vi 
 
ACKNOWLEDGMENT 
 
Above all, I am wholeheartedly thankful to my supervisor, Dr. Sima Tokajian, for 
helping me reach where I stand today. It is very difficult to express how much I 
appreciate your continuous support, guidance, wisdom and encouragement. Not only 
have you been a mentor to me, but also a very dear friend. If I rise to the heights of 
success, I will eternally be grateful to you. 
I would like to direct my thanks to all the faculty members that have been part of my 
six year journey at Lebanese American University. I also extend my recognition to 
my committee members, Dr. Roy Khalaf and Dr. Tarek Nawas, for their contribution 
to my thesis work. I offer my sincerest recognition to Ms. Helena Bou Farah and Ms. 
Maya Farah for their valuable help throughout my undergraduate and graduate years. 
I am considerably thankful to my dearest colleagues, Ms. Christel Dagher, Ms. Tina 
Panossian, Mrs. Natalia Abou Zaki and Mrs. Tamara Salloum, for their love, 
motivational support and for making warm memories at LAU. 
Last but not least, words are not enough to express my gratitude and appreciation for 
my parents and my brother who have always been there for me no matter what and 
constantly inspired me to pursue my dreams. I cannot thank you enough. 
 
 
 
 
 
 
 
 
 
 
vii 
Genome-wide Antibiotic Resistance and Virulence Profiling of 
Pseudomonas aeruginosa Isolated from Clinical Samples in 
Lebanon
Cynthia P. Harb 
ABSTRACT
Extensively drug resistant Pseudomonas aeruginosa (XDR) are a great worldwide 
public health concern. P. aeruginosa is a Gram-negative opportunistic pathogen 
associated with a broad range of infections. It causes acute skin, lung, urinary tract 
infections and sepsis. It can also cause chronic infections in the pulmonary passages 
of individuals with cystic fibrosis. P. aeruginosa is widespread in nature lurking on 
diverse habitats including animals, plants, soil, in-animate objects and hospital 
settings. In this study, 18 P. aeurginosa clinical isolates were collected from the 
American University of Beirut Medical Center in Lebanon and were used for 
identification, phylogenetic analysis and detection of porin (oprL, oprI and oprD), 
efflux pumps (mexA, mexC and mexE) and exotoxin genes (exoU and exoS). Illumina 
paired-end libraries for twelve representative isolates were prepared and sequenced. 
The initial assemblies produced an average genome size of 6.8 Mb, G+C% content of 
65.90-66.30% and 116-396 contigs. In silico MLST typing revealed that the isolates 
belonged to six MLST types: ST-233, ST-235, ST-296, ST-654, ST-1182 and ST-
1233. Antimicrobial susceptibility testing showed that all except PA43, were XDR. 
Genomic analysis revealed the presence of several β-lactamases encoding genes 
(blaPAO, blaOXA-50, blaOXA-4, blaIMP-15, blaGES-1 and/or blaVIM-2 genes) and the aac(6')Ib-
cr gene conferring aminoglycoside resistance. Additionally, all the 18 isolates carried 
mexC and mexE conferring ciprofloxacin resistance. exoS and exoU toxing encoding 
genes were detected in 56% and 39% of the isolates, respectively, and phiCTX was 
the most common detected plasmid in this study. In this study the comparative 
analysis of P. aeruginosa genomes isolated from clinical samples in Lebanon, 
viii 
revealed many antibiotic resistance and virulence factor genes, a large number of 
genes that are involved in regulation, catabolism, transport, and efflux of organic 
compounds contributing to the remarkable ability of this bacterium to adapt to a wide 
range of environmental niches. The emergence and spread of XDR P. aeruginosa, 
which constitute a therapeutic problem of serious concern, emphasize the importance 
of having effective laboratory detection systems and infection control measures. 
Keywords: Pseudomonas aeruginosa, Next-generation sequencing, Genome wide 
analysis, Resistance, XDR, Virulence, Efflux pumps, Lebanon. 
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Chapter One 
 
 
INTRODUCTION 
  Pseudomonas aeruginosa, a member of the family 
Pseudomonadaceae, is considered to be a leading opportunistic pathogen (Darch et 
al., 2015). P. aeruginosa is one of the most abundant microorganisms found in 
nature. Due to its widespread availability, it can increasingly interact with human 
hosts, which in turn results in countless serious infections in the hospital settings and 
environment (Snyder et al., 2013).  This life-threatening Gram-negative bacterium 
can cause a wide range of acute infections such as burns, lungs, urinary tract and 
wound infections and can also contribute to chronic infections in the lungs of patients 
with cystic fibrosis (Wong et al., 2012; Snyder et al., 2013), which are linked to the 
high rate of mortality and morbidity associated with this disease (Marvig et al., 
2013). 
  The switch from an acute infection to a chronic infection is regulated by 
various mechanisms. These mechanisms control the ability of P. aeruginosa to: 
grow, accumulate and colonize the airway passages, grow in the form of biofilms, 
and control host gene expression through quorum sensing (QS). It also resists various 
antibacterial drugs due to its acquired, adaptive and intrinsic resistance mechanisms, 
rendering associated infections to be difficult to combat and eradicate (Darch et al., 
2015; Kim et al., 2011). Most P. aeroginosa strains are extremely resistant to the 
fourth-generation cephalosporins, β-lactam drugs and many others, with some strains 
still exhibiting susceptibility to colistin and amikacin (Kos et al., 2014).  
 Consequently, it is of major importance to determine and thoroughly study 
the antibiotic resistance profiles of P. aeruginosa local strains with the purpose of 
precisely identifying the antimicrobial drug of choice and treatment measures to 
combat pseudomonal infections. All genetic elements and factors pertaining to 
antimicrobial drug resistance must be identified via molecular tests (Bentzmann et 
al., 2011). In addition to antibiotic resistance control and surveillance, the high-
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throughput whole genome sequencing (WGS) approach is useful in analyzing the 
potential adaptation and evolution of P. aeruginosa over time (Snyder et al., 2013; 
Koser et al., 2014). 
The overall objectives of this study are stated as follows: 
 To compare the differences that exist between the P. aeruginosa local 
isolates 
 To determine the evolutionary dynamics of P. aeruginosa local strains 
in terms of genome plasticity  
 To determine the presence of resistance (mexA, mexC, mexE and 
oprD) and virulence genes (exoS and exoU) through PCR assays and 
compare to those identified from high-throughput sequencing 
 To identify intrinsic resistance including mutations in the ftsK gene, 
which affects cell division and ampG gene, which is responsible for β-
lactamase production 
 To detect the presence of the AmpR β-lactamase regulator for positive 
regulation of the QS virulence genes 
 To screen the P. aeruginosa genomes for the presence of the type III 
secretion system effectors 
 To correlate antibiotic resistance to the presence of mexA, mexC and 
mexE efflux pump genes 
 To construct a pylogenetic tree using whole-genome sequencing data 
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Chapter Two 
 
LITERATURE REVIEW 
2.1. Overview on Pseudomonas aeruginosa 
P. aeruginosa is a clinically important aerobic, rod-shaped Gram-negative bacterium. 
The length of this opportunistic pathogen varies from approximately 1 µm to 5 µm, 
and the width ranges from about 0.5 µm to 1 µm (Sedighi et al., 2015). It grows as a 
distinct greenish-blue colony due to the production of pycocanin pigment (Gellatly & 
Hancock, 2013), with high phenotypic diversity ranging from motile to non-motile 
and mucoid to non-mucoid (Workentine et al., 2013). It has the ability to thrive in a 
variety of habitats due to the fact that it requires nominal nutrient concentrations. It is 
ubiquitous in soil, plants, animals and on inanimate surfaces (Nasreen et al., 2015). 
It’s also found but to a lower extent on the skin and in the gastrointestinal tracts of 
humans (Sedighi et al., 2015).  
It is characterized by having a mosaic genome with 90% of its genes or more 
encompassing the conserved core region. Strains are differentiated by a specific set 
of genes disrupting the conserved core. These segments, which are strain-specific, 
are found in the genome plasticity regions at limited chromosomal positions. This 
suggests that the genome among diverse pseudomonal strains is highly conserved 
despite the fact that some genomic islands have been encountered (Bentzmann & 
Plesait, 2011). P. aeruginosa PAO1 was the first strain to be sequenced, and its 
genome is composed of a circular chromosome of 6.264 Mb and includes 5570 
protein coding sequences. Subsequently, other strains were sequenced including: 
PA14, LESB58 and PA7 (Klockgether et al., 2011). P. aeruginosa PA7 whole 
genome sequence has been studied as a taxonomic outlier consisting of 6,588,339 bp. 
It contains 51 genome plasticity regions and several genomic islands, and showed 
95% similarity match compared to other isolates (Roy et al., 2010). 
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2.2. Resistance 
P. aeruginosa can be characterized as being a multi-drug resistant, extensively-drug 
resistant or pan-drug resistant bacterium having several intrinsic resistance 
mechanisms rendering several antibiotics to be ineffective. (MDR: non-susceptible 
to ≥1 agent in ≥3 antimicrobial categories; XDR: non-susceptible to ≥1 agent in all 
but ≥2 categories; PDR: non-susceptible to all antimicrobial agents). (Bonomo et al., 
2006; Livermore, 2002, Magiarakos et al., 2011).  
2.2.1. Epidemiology of Resistance 
In the past 20 years, P. aeruginosa has progressively become more resistant to 
carbapenem, fluoroquinolone and third-generation cephalosporin treatments (Flamm 
et al., 2004). Upon the beginning of anti-pseudomonal treatment, intubated patients 
in critical care units can become multi-drug resistant in a period as short as ten days. 
Also, strains that are found to be resistant to ciprofloxacin and piperacillin show 
increasing degrees of resistance to other antimicrobial drugs compared to strains 
that are sensitive to ciprofloxacin and piperacillin (Sun et al., 2011). 
2.2.2. Intrinsic Resistance Mechanisms of P. aeruginosa 
The most important resistance mechanism within P. aeruginosa is the low 
permeability of its outer membrane which functions as a selective barrier reducing 
antibiotic uptake. The outer membrane of P. aueroginosa is characterized by the 
presence of an insufficient number of its major small porin channels OprF, and 
inefficient number of porins specific for the uptake of antibiotics such as OprB and 
OprD (Gellatly & Hancock, 2013). There are additional pathways for antibiotic 
uptake across the cell such as: hydrophobic molecule uptake through the 
phospholipid bilayer and self-driven polycationic antibiotic passage (Breidenstein et 
al., 2011). Resistance could be also due to rapid efflux, which is caused by the 
upregulation of efflux pumps expression, and the production of AmpC β-lactamases 
benefiting from the slow passage as a result of lower outer membrane permeability 
(Gellatly & Hancock, 2013). 
Another intrinsic resistance mechanism is the simultaneous involvement of 
numerous unrelated genes and various mutations in the resistome of P. aeruginosa. 
Intrinsic resistance to ciprofloxacin and β-lactams is prevalent in strains that have 
5 
 
mutations in the ftsK gene which affects cell division, while resistance to β-lactams 
is linked to mutations in the gene ampG, which is responsible for β-lactamase 
production. Therefore, the increased intrinsic resistance to most antibacterial drugs 
is attributed to the synchronized action of multiple mechanisms (Breidenstein et al., 
2011). 
2.2.3. Acquired Resistance  
Acquired resistance is directly related to the reduced susceptibility of P. aeruginosa 
and is divided into two forms: horizontal gene transfer and mutational resistance. 
Antibiotic resistance genes can be obtained via conjugation, transformation and 
transduction, and are carried on mobile genetic elements such as: plasmids, 
transposons and prophages. The presence of multiple antibiotic resistance genes on 
plasmids can result in multi-drug resistant strains. This is mostly the case with 
resistance to aminglycosides and β-lactams. Mutational resistance is another type of 
acquired resistance. Additionally, agents damaging genetic material and bacterial 
proliferation in biofilms increase the frequency of mutations (Blair et al., 2015). 
Mutations that result in antibiotic uptake reduction, antibiotic target modification, β-
lactamase overproduction and efflux pump overexpression render P. aeruginosa 
insusceptible to antimicrobial treatment. One example of mutational resistance 
mechanism is associated with mutations in genes encoding mexR and nfxB resulting 
in efflux pumps MexAB-OprM and MexCD-OprJ derepression. A mutation in the 
gene encoding mexZ is involved in overexpression of MexXY-OprM resulting in 
resistance to aminoglycosides, fluoroquinolones and cefepimes. Resistance to the 
antibacterial drug imipenem results from mutation in OrpD, while resistance to a 
variety of antibiotics, including imipenem, is generated by mexT and mexS 
mutations, which boost the efflux pump MexEF-OprN and decrease OrpD 
expression. Mutational resistance is also linked to mutations in AmpD and AmpC β-
lactamase effectors, which leads to the increase in β-lactamase production 
(Breidenstein et al., 2011). Finally, fluoroquinolone resistance can also be attributed 
to mutations in gyrases (gyrA and gyrB) and topoisomerase IV (parC and parE) 
(Salma et al., 2012). 
Therefore, accumulation of mutations can cause increased resistance. Creeping 
baselines is a step-wise process that converts low-level resistance to increased high-
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level resistance through the combination of multiple mutations in due course. For 
example, three mutations in three distinct genes revealed an increase in tobramycin 
resistance by two times. However, resistance was augmented to 16-fold with the 
addition of a forth mutation (Breidenstein et al., 2011). An example of this is seen in 
aminoglycoside resistance, which includes mutations in diverse genes that encode 
DNA duplication, energy metabolism and lipopolysaccharide production. 
Fluoroquinolone resistance, on the other hand, is mediated by mutations in genes 
that encode efflux pump regulators, iron transport, and prophage. Thus, acquired 
resistance to a set of antibacterial drugs can occur due to numerous mutations in 
distinct genes (Mortita et al., 2015; Poole & McKay, 2003). 
2.2.4. Adaptive Resistance 
Bacteria develop adaptive resistance as a consequence of prolonged antibiotic 
treatment or the presence of a stimulus. Adaptive resistance is attained by a vast 
number of stimuli and conditions including: anaerobiosis, antibiotics, biocides, 
biofilm formation, cations, carbon resources, polyamines and swarming (Gellatly & 
Hancock, 2013). Such factors act by influencing the genes that control efflux 
pumps, enzymes and lipopolysaccharides. Adaptive resistance is pivotal in P. 
aeruginosa because its genome consists of a large percentage of regulatory genes. It 
is capable of resisting antibiotic action due to sub-inhibitory antibiotic dosage and 
environmental stimuli that modulate its gene expression (Fernandez & Hancock, 
2012).  
Aminoglycosides and polymyxins belong to polycationic antimicrobials, which 
undergo self-driven uptake across the bacterial outer membrane by attaching to 
specific binding sites on the lipopolysaccharide (Breidenstein et al., 2011). Their 
passage is limited by the action of arnBCADTEF operon, which allows the binding 
of 4-aminoarabinose to Lipid A. Minimal amounts of divalent cations lead to 
polycationic antimicrobial resistance. This mechanism involves the introduction of 
the arn operon and the activation of PhoPQ and PmrAB regulatory systems. The 
function of the arn operon is reducing cation amounts upon stimulation in biofilms 
(Poole, 2011). PhoPQ and PmrAB control the lipolysaccharide modification 
arnBCADTEFpmrE operon in order to achieve resistance against cationic 
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antimicrobial peptides and polymyxin B under conditions of depleted cation 
concentration (Balasubramanian et al., 2012). 
Another important mechanism of adaptive resistance involves the production of 
AmpC β-lactamases. β-lactamases inactivate β-lactam drugs. Upon the introduction 
of β-lactamases, cefotaxime, ceftazidime and penicillins can longer be used to 
effectively treat P. aeruginosa associated infections, as their main mode of action 
relies on ampC gene upregulation (Fernandez & Hancock, 2012). 
The excessive expression of efflux pump genes is another means of adaptive 
resistance which is induced due to antibiotic sub-inhibitory dosages. MexXY efflux 
pump genes are overexpressed by the introduction of aminoglycosides. This results 
in adaptive resistance due to the quick outward flow of the aminoglycoside 
conferring multi-drug restistance (Fernandez & Hancock, 2012). This is observed in 
bacterial colonies growing in biofilms, where resistance is achieved through several 
mechanisms (Hoiby et al., 2010). One way includes mutation in the quorum sensing 
regulatory network resulting in the increased expression of genes that encode efflux 
pumps and enzymes. Another mode of resistance involves varying amounts of 
nutrient uptake causing diversity in the metabolic activities of different isolates 
(Breidenstein et al., 2011). Bacterial cells found in the interior of the growing 
biofilm are more likely to be metabolically inactive, while the bacterial cells found 
on the surface of the biofilm grow much faster, hence different antibiotics target 
different biofilm areas. Polymyxins target the interior cells, while β-lactams and 
aminoglycosides only affect the external layer. Biofilms, in addition, are described 
as being rich in persister cells with a lower percentage of planktonic cells. Persister 
cells are capable of surviving the harsh conditions of antibiotic pressure due to their 
slow growing nature, with little being known about the mechanism (Poole, 2011). 
A particular type of movement carried out by P. aeruginosa is called swarming, and 
is unrelated to flagella-mediated swimming and pilus-mediated twitching. 
Dysregulation in more than 400 genes involved in adaptation, metabolic pathways, 
motility, regulation and secretion causes pseudomonal swarming in the lungs owing 
to its viscous nature and poor nitrogen availability. lasB and pvdQ are two virulence 
genes that are most needed for swarming (Overhage et al., 2008). Isolates that move 
by swarming are usually more resistant to a variety of antimicrobial drugs. They 
8 
 
also carry numerous virulence factors, genes and toxins. Adaptive resistance occurs 
in swarming cells by the dysregulation of a sensor kinase, PhoQ, which is mediated 
by two swarming regulators, Lon and CbrA (Poole, 2011; Sampedro et al., 2014).  
Tokajian et al. (2012) studied the resistance pattern of 100 P. aeruginosa isolates 
collected mainly from tracheal aspirates, urine, sputum, pus and wounds. The study 
revealed that 25% of the isolates were resistant to impenem and pipercillin-
tozabactam, while 29% were resistant to ceftazidime. Resistance was measured 
against the antibiotics mostly used in Lebanon to treat pseudomonal infections 
(Tokajian et al., 2012). On the other hand, Salma et al. (2012) reported that resistance 
to fluoroquinolones was due to one or more mutations in DNA gyrases and 
topoisomerase IV specifically in the gyrA and parC genes. Resistance to 
carbapenems was also detected in the Mediterranean region and was mainly linked to 
the production of carbapenemases (VIM-2 and IMP-15) and mutations in the oprD 
gene (Al Bayssari et al., 2014). Carbapenem resistant strains harboring the VIM-2 
carbapenemase have disseminated into livestock animals in Lebanon posing a threat 
on humans (AL Bayssari et al., 2015).  
2.3. Virulence Regulatory Systems of P. aeruginosa 
2.3.1. Quorum Sensing 
Quorum sensing (QS) is a mechanism used by bacteria to control the expression of 
different genes, during which bacterial cells synthesize small molecules called 
autoinducers. These molecules allow the continued existence of the bacterial cells 
upon diffusion when a certain concentration is met. The main reason behind 
utilizing the QS mechanism is to control the synthesis of virulence contributing 
factors including production of biofilms, expression of efflux pumps and motility. 
P. aeruginosa uses the QS system by means of two autoinducers: AHLs (N-acyl-
homoserine lactones) and AQs (2-alkyl-4 quinolones) (Lee & Zhang, 2014). 
2.3.1.1. AHL-mediated QS 
The las and rhl systems are two AHL-mediated QS systems. lasI and rhlI lead to the 
activation of a family of regulators, LuxR, LasR or RhlR, by binding to them, 
resulting in multimer interactions due to their AHL occurrence (Balasubramanian et 
al., 2012).   
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2.3.1.2. AQ-mediated QS 
PQS (2-heptyl-3-hydroxy-4-quinolone) and HHQ (2-heptyl-4-quinolone) are two 
AQ-mediated QS signals. Both of them allow the binding of the pqsABCDE operon 
promoter to LysR transcription regulator, MvfR. Hence, both PQS and HHQ act as 
effectors of MvfR. Because it is capable of sequestering iron molecules, PQS can 
influence the Fur regulon expression and can synthesize vesicles through membrane 
conformational changes. However, PmpR is a negative regulator of MvfR and is a 
YebC component (Gellatly & Hancock, 2013). 
2.3.1.3. QS Regulation 
QS genes are adjusted by global regulators such as the RpoS (Lee & Zhang, 2014). 
lasR and rhlR are modulated by RpoS. Another main global regulator is RsaL which 
plays a pivotal role in las signaling, regulates the expression of approximately 130 
genes, specifically hydrogen cyanide and pyocyanin genes which are involved in 
AHL-related virulence repression, and is also implicated in the conversion from a 
planktonic status to a sessile status.  CzcR is another regulator that binds to the 
promoter of lasI allowing lasI, rhlI and rhlR expression resulting in decreased 
susceptibility to carbapenems and heavy metals (Balasubramanian et al., 2012).  
VqsR is another major regulator inhibiting QscR, the LuxR regulator, which in turn 
controls QS. QscR binds to LasR and RhlR and is required for the homeostasis of 
LasI (Liang et al., 2012). At the post-transcriptional level, LasR and RhlR are 
destabilized by the action of QteE. However, the QS threshold concentration, which 
is necessary for specific QS gene activation, drops to zero when qteE is absent. AHL 
amounts also drop upon subsequent activity of RsmA which is known for its negative 
effect on rhl and las pathways. Conversely, a positive regulator of rhlI is the RNA 
chaperone Hfq (Balasubramanian et al., 2012).  
The most recent global regulator is the AmpR β-lactamase regulator, which 
positively regulates the QS genes (Balasubramanian et al., 2012). P. aeruginosa 
strains that do not harbor AmpR produce a very minute quantity of QS related 
virulence determinants, mainly LasA and LasB proteases and pycocanin. AmpR is 
10 
 
involved in preserving P. aeruginosa infections at the acute level and controlling 
non-β-lactam resistance (quinolones and aminoglycosides) (Kumari et al., 2014) by 
repressing efflux pump MexEF-OprN activity, production of biofilms, AlgT/U 
alignate regulator, expression of QS genes and production of pycocanin 
(Balasubramanian et al., 2012). 
2.3.2. Two-Component Regulatory Systems 
TCS are two-component regulatory systems implicated in cellular signaling. TCS 
consists of two constituents: a cytoplasmic response regulator (RR) and an integral 
membrane sensory histidine kinase (HK). A conserved acceptor domain and a 
variable donor domain compromise the RR (Balasubramanian et al., 2012). The HK 
C-terminal domain consists of a catalytic domain, a dimerization domain and a 
conserved histidine molecule. The HK utilizes its N-terminal domain in order to 
sense particular stimuli. The signaling process involves the dimerization of two HK 
molecules followed by phosphorelation at the histidine molecule. This occurs when 
the HK residues receive a signal. The receiver domain of RR accepts the phosphate 
and aids in its catalysis. The phosphate is added to its aspartate residue. This causes 
the donor domain, which often binds to DNA, to undergo a conformational change 
affecting the level of gene expression (Bentzmann & Plesait, 2011). 
P. aeruginosa is characterized by having a great number of TCS proteins. The ability 
of P. aeruginosa to control its antibiotic resistance, metabolic activities and virulence 
is contributed to the vast amount of TCS proteins available. GacSA is the most 
important TCS protein found in P. aerurginosa, which is responsible for converting 
an acute infection into a chronic infection.  
It also has a major role in the formation of biofilms, expression of virulence factors, 
metabolites and QS. Antibacterial drug resistance to ciprofloxacin, tetracycline and 
tobramycin is achieved by GacSA through the action of RsmA/rgRsmZ 
(Balasubramanian et al., 2013). The binary interaction of two additional TCSs in P. 
aeruginosa, PhoPQ and PmrAB, has a considerable effect on its virulence. 
2.3.3. Biofilm Formation 
P. aeruginosa isolates grow rapidly in biofilms, which generally occurs in patients 
with cystic fibrosis. Its increased resistance to a variety of antimicrobial drugs and to 
the immune system defense mechanisms results from its ability to form biofilms. Its 
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expanded resistance is mainly due to the presence of biofilm persister cells, which 
are produced by algR and pilH genes (Mulcahy et al., 2010; Poole, 2011). The 
process of biofilm cell lysis is achieved by the QS system, producing extracellular 
DNA required for bacterial biofilm formation. Rhamnolipid production is also 
controlled by the QS system, which generates the cap part of the biofilm mushroom. 
Rhamnolipid also preserves the channels of the mature biofilms and assists in biofilm 
movement (Harmsen et al., 2010).  
2.3.4. Alginate Production 
When switching from an acute infection to a chronic infection, the phenotype of P. 
aeruginosa isolates found in a patient suffering from cystic fibrosis changes from 
non-mucoid to mucoid cells with overproduction of alginate (Gellatly & Hancock, 
2013). The lung foci are the restricted areas invaded by the chronic infection, and 
lung tissue are seriously damaged as a result of these foci disrupting regular lung 
activity. The microorganism is shielded from the action of antimicrobial drugs and 
phagocytosis owing to the synthesis of alignate (Bjarnsholt et al., 2010). However, 
this mucoid phenotype appears after antibiotics, hydrogen peroxide and leucocytes 
are given to eliminate the biofilm (Balasubramanian et al., 2012). 
The chief factor in alginate production is the σ factor AlgT/U. MucA and MucB are 
two anti-σ factors that inhibit σ factor AlgT/U at the post-transcription level. When 
MucA and MucB lose their activity via mutations, mucoid cells appear. This takes 
place when a coordinated proteolytic pathway leads to the detachment of MucA from 
σ factor AlgT/U (Damron & Goldberg, 2012). The connection between alginate 
synthesis and antimicrobial drug resistance is AmpR. AmpR also negatively controls 
the expression of algT/U by interacting with QS. However, since it is a complex 
process, AlgT/U needs to regulate the action of several transcription regulators 
simultaneously (Balasubramanian et al., 2011). 
2.3.5. Iron Uptake Regulation 
The presence of iron is very vital, where toxic oxygen reactive species are created in 
response to a surplus of iron molecules. In order to find iron and bind to it, bacteria 
develop siderophores such as: pyochelin and pyoverdine. P. aeruginosa also utilizes 
a ferric uptake regulator called Fur, with its main function being to bind to the Fur 
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box to regulate the iron regulon and control other regulator expressions (Cornelis, 
2010). 
The expression of P. aeruginosa virulence factors are affected by the iron 
concentration. The correlation between the amount of iron and the expression of 
virulence factors is related to PvdS.  PvdS regulates pyoverdine and pyoverdine 
receptor synthesis and PrpL and exotoxin A virulence factors, hence linking iron to 
virulence. In addition, lactoferrin prevents biofilm formation showing that iron plays 
a major role in the process. However, formation of biofilms is determined by the 
concentration of iron in the cell, but formation of biofilms is inhibited with superior 
iron amounts (Jimenez et al., 2012). 
Minute concentrations of iron improve the functions of the QS systems. What the QS 
system regulators do is that they activate transcription by controlling an iron 
responsive gene, MvfR, when iron concentrations are minimal. Furthermore, the 
synthesis of PQS is positively regulated by small RNA molecules which are 
negatively regulated by Fur. Pyochelin and pyoverdine can more easily search for 
iron molecules in the cell due to PQS chelating iron (Balasubramanian et al., 2012). 
2.3.6. Toxins and Exoproteins 
 Toxins and exoproteins strongly contribute to the virulence of P. aeruginosa. It 
contains a total of five secretion systems out of seven with numerous toxins. Of 
utmost importance is the type III secretion system. The type III secretion system 
injects ExoS, ExoT, ExoU and ExoY bacterial effector proteins directly into the host 
cell cytoplasm. Strains that contain ExoS and ExoU are more likely to be multi-drug 
resistant. Specifically, isolates that are ExoS positive can result in reduced DNA 
production, while isolates that are ExoU positive have the ability to combat the 
eukaryotic immune system. Besides, severe lung infections are associated with the 
presence of ExoS, which can lead to chronic disruption of the respiratory tract 
(Kipnis et al., 2012). Strains that harbor toxin genes are characterized by increasing 
the severity of the disease and symptoms, and are treated with anti-pseudomonal 
drugs resulting in drug resistance (Wong-Beringer et al., 2008). 
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2.3.7. Regulatory RNAs 
In P. aeruginosa, regulatory RNAs (rgRNAs) are a necessary factor for the 
expression of virulence genes. rgRsmY and rgRsmZ are two important rgRNAs, 
which are required for the alteration from an acute infection into a chronic one. 
These two rgRNAs are positively regulated by GacA TCS, which proceeds by 
sequestering RsmA (RNA-binding protein) resulting in virulence factor expression 
dysregulation (Bentzamann & Plesait, 2011).  
Additionally, translation can be inhibited by the action of antisense sRNAs (asRNAs) 
in P. aeruginosa strains by interacting with mRNAs. The expression of pyocyanin 
and PQS are influenced by asPhrS, an example of an asRNA. As mentioned 
previously, iron uptake is regulated by small RNA molecules, specifically, asRNAs 
which include asPrrF and asPrrF2. At conditions of high iron concentrations, Fur 
inhibits the two asRNAs. However, at conditions of iron-depletion, Fur activates the 
two asRNAs, which, interact with the mRNA of target genes such as superoxide 
dismutase sodB gene. Therefore, iron uptake, carbon metabolism and virulence work 
in synchrony due to regulation by asPrrF1 and asPrrF2. asPrrH is an additional 
asRNA regulating virulence mechanisms in P. aeruginosa which is activated at low 
iron concentrations (Balasubramanian et al., 2012). 
2.4. Multi-drug Resistant P. aeruginosa Treatment 
 The antibiotic treatment needed for full eradication of this deadly pathogen is 
challenging due to the multiple antibiotic resistance mechanisms that it possesses. 
The most effective treatment determined is the use of an anti-pseudomonal β-lactam 
drug along with an aminoglycoside, or the use of an anti-pseudomonal β-lactam drug 
along with an anti-pseudomonal quinolone. However, it was suggested that β-lactams 
should be utilized more frequently than quinolones since β-lactam antibiotics were 
more effective in combating this microorganism. Developing resistance to 
quinolones is a much faster process. The optimum treatment involves one dosage of 
aminoglycoside antibiotic per day over a period of a maximum of five days. In some 
situations in intensive care units, polymyxins such as colistin are used as a last choice 
(Sun, 2011).  
Antibiotic treatment can be replaced by other therapeutics such as bacteriophage 
treatment. In general, bacteriophages increase in number at the site of bacterial 
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infection, act on the bacterium of choice regardless of the normal flora and can 
interact with the antibiotic resistant bacteria. These are the three key differences 
between bacteriophage treatment and antibiotic treatment.  Upon administration of 
bacteriophage treatment into the respiratory tract by nebulization, bacteriophages can 
stimulate host phagocytes to kill the pathogenic bacteria limiting their ability to 
initiate an infection in the lungs in cases of cystic fibrosis (Debarbieux et al., 2010). 
2.5. High-throughput Whole Genome Sequencing 
Before the discovery of the whole genome sequencing (WGS) approach, information 
on bacterial phylogeny was limited, and relationships among different pathogens 
were lacking. The emergence of high-throughput WGS along with bioinformatics 
techniques such as multi-locus sequence typing (MLST) allows the construction of 
phylogenetic trees and identification of the genetic structures of bacterial species 
(Klemm & Dougan, 2016). High-throughput WGS also drove the development of 
SNP-based phylogenetic analysis which proved to be useful in determining the 
relationship between genetic diversity and different niches for pathogenic bacteria, 
hence uncovering the epidemiology of outbreaks in hospital settings. The feasibility 
of these technological advances has facilitated the development of transmission 
mapping while identifying pathogen diversity within the host. This means that WGS 
has allowed microbiologists to monitor bacterial evolution and investigate the spread 
of bacterial pathogens at different scales (globally, locally and within a single 
patient). It can also allow the identification of previously unknown microorganisms, 
virulence factors and antibiotic resistance determinants (Robinson et al., 2013). 
High-throughput WGS has also proved to be useful in the development of 
antimicrobial drugs and vaccines. By combining WGS with SNP-based analysis, 
novel antibiotic targets can be determined by comparing the SNPS in the genomes of 
a sensitive bacterial parent strain and a resistant bacterial daughter strain (Loman & 
Pallen, 2015). Thus, high-throughput sequencing promises to be an effective 
approach for identifying, screening and preventing future threats to public health 
(Koser et al., 2014). 
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Chapter Three 
 
MATERIALS AND METHODS 
3.1. Clinical Isolates 
Eighteen P. aeurginosa clinical isolates were collected from the American University 
Medical Center and were used for genome analysis. The isolates were recovered 
from bile, blood, catheter tip, sputum, tracheal-aspirate and urine, collected from 
nine females and nine males including two juniors (1-17 years), six adults (18-64 
years) and ten seniors (>64 years). Isolates were designated as: PA3, PA5, PA9, 
PA15, PA16, PA28, PA 43, PA45, PA53, PA59, PA120, PA132, PA138, PA141, 
PA147, PA152, PA155 and PA177. All were cultured on Tryptic Soy Agar (TSA) 
(Bio-Rad, U.S.A) media at 37oC for 24-48 h. 
3.2. DNA Extraction 
Bacterial DNA was extracted using the NucleoSpin kit (MACHEREY-NAGEL, 
Germany) and following the manufacturer’s instructions. 
3.3. Genome Sequencing 
The Qubit 3.0 fluorometer (Life technologies, Carlsbad, CA) was utilized for 
accurately quantifying the DNA concentrations.  Genomic DNA was used as input 
for library preparation using the Illumina Nextera XT library preparation kit 
(Illumina, Inc., San Diego, CA). The Agencourt AMPure XP PCR purification beads 
(Agencourt, Brea, CA) were used to allow effective clean up after library 
preparation. With the use of the Kapa library quantification kit (Kapa Biosystems, 
Woburn, MA), the CFX96-PCR system (Bio-Rad, U.S.A) was utilized to quantify 
the DNA libraries. The Illumina MiSeq Desktop Sequencer was finally used to 
multiplex, cluster and sequence the pooled libraries with a minimum of 250 bp read 
length.  
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3.4. PCR Assays 
3.4.1. Detection of Outer Membrane Protein Encoding Genes  
PCR assays were performed using the following primers: oprI F (5’-
ATGAACAACGTTCTGAAATTCTCTGCT-3’) and oprI R (5’- 
CTTGCGGCTGGCTTTTTCCAG-3’) amplifying a 249 bp fragment of the oprI 
gene, oprL F (5’-ATGGAAATGCTGAAATTCGGC-3’) and oprL R (5’- 
CTTCTTCAGCTCGACGCGACG) amplifying a 504 bp fragment of the oprL gene, 
oprD F (5’- CGCCGACAAGAAGAACTAGC-3’) and oprD R (5'- 
GTCGATTACAGGATCGACAG-3’) amplifying a 1412 bp of the oprD gene (Adabi 
et al., 2015; Poonsuk et al., 2014). PCR mixture contained 2 µl of template DNA, 20 
µM of each pair of primers, 25 mM MgCl2, 2 mM dNTPs and PCR-grade sterile 
water achieving a final volume of 20 µL. The cycling conditions were: 1 cycle was 
set at 95˚C for 12 min followed by 30 cycles at 94˚C for 30 sec for denaturation, 1 
cycle was set at 63˚C for 30 sec for annealing and finally, 1 cycle was set at 72˚C for 
1 min followed by 1 cycle at 72˚C for 10 min for elongation. The PCRs were 
performed on a thermal cycler (Bio-Rad). 
3.4.2. Detection of Efflux Pump Encoding Genes 
PCR assays were performed using the following primers: mexA F (5’- 
CGACCAGGCCGTGAGCAAGCAGC-3’) and mexA R (5’- 
GGAGACCTTCGCCGCGTTGTCGC-3’) amplifying a 316 bp fragment of the 
mexA gene, mexC F (5’- GTACCGGCGTCATGCAGGGTTC-3’) and mexC R (5’- 
TTACTGTTGCGGCGCAGGTGACT-3’) amplifying a 164 bp fragment of the 
mexC gene and mexE F (5’- CCAGGACCAGCACGAACTTCTTGC-3’) and mexE 
R (5’- CGACAACGCCAAGGGCGAGTTCACC-3’) amplifying a 114 bp fragment 
of mexE gene (Adabi et al., 2015; Llanes et al., 2004). PCR mixture contained 2 µl of 
template DNA, 20 µM of each pair of primers, 25 mM MgCl2, 2 mM dNTPs and 
PCR-grade sterile water achieving a final volume of 20 µL. The cycling conditions 
were: 1 cycle was set at 95˚C for 12 min followed by 30 cycles at 94˚C for 30 sec for 
denaturation, 1 cycle was set at 63˚C for 30 sec for annealing and finally, 1 cycle was 
set at 72˚C for 1 min followed by 1 cycle at 72˚C for 10 min for elongation. The 
PCRs were performed on a thermal cycler (Bio-Rad). 
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3.5. Antibiotic Susceptibility Test 
Antibiotic susceptibility for the 18 pseudomonal strains was determined by the 
Kirby-Bauer disk agar diffusion method against 12 different antibiotics including: 
amikacin (AK), aztreonam (ATM), carbencilin (CAR), ceftazidime (CAZ), 
ceftriaxone (TX), ciproflaxin (CI), colistin (CST), gentamicin (GM), imipenem 
(IPM), piperacillin/tazobactam (TZP), tetracycline (TE) and tobramycin (TM). The 
bacterial-saline suspensions were adjusted to 0.5 Mcfarland standard. The test was 
performed on Mueller-Hinton agar followed by incubation at 37oC for 24 h. The 
Clinical and Laboratory Standards Institute (CLSI) guidelines were used to 
determine the antibiotic resistance/susceptibility profiles for each respective 
antimicrobial drug (CLSI, 2013). 
3.6. Analysis of Sequencing Results 
3.6.1. Genome Assembly  
De novo assembly was performed for the sequenced genomes by using the A5-miseq 
assembly pipeline (Tritt et al, 2012; Coil et al, 2015). The assembly was performed 
simultaneously with error correction, cleaning of data, control of quality and 
scaffolding (Tritt et al., 2012). . 
3.6.2. Genome Annotation Using RAST 
The de novo genome assemblies were annotated using RAST (http://rast.nmpdr.org) 
(Aziz et al, 2012). Genes encoding rRNA, tRNA and proteins were determined. The 
specific functions of each gene and the interaction systems of each genome were also 
identified (Aziz et al., 2008; Overbeek et al., 2014).  
3.6.3. Determination of Resistance Genes 
The bacterial genomes were analyzed using The Center for Genomic Epidemiology 
(CGE) website (www.genomicepidemiology.org) along with the SEED viewer 
service. Genes encoding antibiotic resistance were identified by the ResFinder 2.1 
web server (Zankari et al., 2012).  
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3.6.4. Multi-Locus Sequence Typing (MLST) and Plasmid Detection 
The CGE website includes a MLST 1.7 server which was used to determine the 
MLST of each sequenced isolate (Larsen et al, 2012). The CGE website also has a 
PlasmidFinder 1.2 web service that was used for detecting plasmids (Carattoli et al, 
2014). 
 3.7. Phage Detection 
The Phage Search Tool (PHAST) was used to detect the presence of phage 
sequences. RAST was used subsequently to annotate the phage genes (Zhou et al., 
2011). 
3.8. Phylogenetic Tree Construction 
Phylogenetic tree construction was generated using Phylosift. The maximum 
likelihood tree was then inferred using FigTree v1.4.3. Six reference genomes DK2, 
LESB58, M18, NCGM2.S1, PAO1 and UCBPP-PA14 were downloaded from 
NCBI. 
3.9. Circular Genomes 
Informative figures of the bacterial circular genomes were obtained using the 
DNAPlotter release 1.11 (Carver et al., 2009), while a comparative figure was 
generated using the CGView server (Grant & Stothard, 2008). 
 
 
 
 
 
19 
 
Chapter Four 
 
RESULTS 
4.1. Sequencing Results 
4.1.1. Genome Assembly Data 
Whole genome sequencing was performed on 12 out of the 18 clinical isolates. The 
average genome size ranged between 6,579,978-7,009,409 bp, G+C% content 
between 65.90-66.30%, number of contigs 116-396, subsystems 566-583, coding 
sequences 6082-6559 and RNAs 61-69 (Table 1). 
Table 1: Genomic features of P. aeruginosa 
Isolate Total 
length 
(bp) 
G+C% No. of 
contigs 
No. of 
subsystems 
No. of 
coding 
sequence 
No. of 
RNAs 
PA9 6,848,493  66.11 247 579 6380 66 
PA15 7,005,560 66.00 116 583 6559 62 
PA16 7,007,890 66.00 125 583 6557 61 
PA28 7,007,723 66.00 118 583 6566 61 
PA43 6,647,372 66.30 189 574 6178 65 
PA45 7,009,409 66.00 120 582 6559 61 
PA59 6,756,856 66.14 171 573 6292 64 
PA120 6,624,004 66.10 122 566 6089 65 
PA132 6,984,014 65.90 139 576 6485 67 
PA141 6,757,082 66.08 178 573 6328 66 
PA152 7,001,596 65.90 396 580 6506 69 
PA155 6,579,978 66.11 204 569 6082 63 
 
Individual MLST types and profiles of the 12 isolates were also obtained, and the 
results showed that the sequenced isolates belonged to different sequence types with 
the most common being ST-233 (Table 2). 
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Table 2: MLST types and profiles of the 12 sequenced P. aeruginosa isolates along 
with their site of isolation/infection 
Clinical Isolate Site of Isolation MLST Type MLST Profile 
PA9 Catheter tip ST-233 16,5,30,11,4,31,41 
PA15 Tracheal aspirate ST-233 16,5,30,11,4,31,41 
PA16 Tracheal aspirate ST-233 16,5,30,11,4,31,41 
PA28 Tracheal aspirate ST-233 16,5,30,11,4,31,41 
PA43 Tracheal aspirate ST-308 13,4,5,5,12,7,15 
PA45 Tracheal aspirate ST-233 16,5,30,11,4,31,41 
PA59 Sputum ST-235 38,11,3,13,1,2,4 
PA120 Tracheal aspirate ST-1182 5,1,109,54,1,1,47 
PA132 Blood ST-235 38,11,3,13,1,2,4 
PA 141 Sputum ST-296 44,8,5,3,15,6,26 
PA 152 Urine ST-654 17,5,26,3,4,4,26 
PA 155 Tracheal aspirate ST-1233 17,5,11,3,4,6,7 
MLST, multilocus sequence typing; ST: sequence type. MLST genes are: acs, aro, 
gua, mut, nuo, pps and trp. 
 
 
Figure 1. Subsystem category distribution of PA59 based on SEED databases 
A total of 4719 subsystems were detected using RAST within the sequenced 
genomes, with the biggest subsystem being the genes encoding nutrient metabolism, 
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followed by those linked to stress response, virulence factors, regulation and cell 
signaling and phages (Figure 1). 
4.1.2. Virulence Determinants 
Virulence determinants were detected using the CGE VirulenceFinder 1.2 tool (Table 
3). lasI and lasR genes, which are very important components of the quorum sensing 
network controlling virulence factors such as cell survival, biofilm formation and 
efflux pumps leading to enhanced pathogenesis (Balasubramanian et al., 2012), were 
detected in 11 out of the 12 sequenced isolates (PA28 and PA132 negative for  lasI 
and lasR, respectively).  exoU or exoS, T3SS effectors, were detected in  nine 
isolates, with all being additionally XDR. Isolates PA9, PA45, PA59, PA120,  
PA132 and PA141 were positive for the exoU gene, a potent cytotoxin required for 
full pseudomonal virulence, PA9, PA15, PA16, PA45, PA152 and PA155 harbored 
the exoS and PA45 exoS and exoU. Finally, gacA and gacS were detected in all the 
sequenced genomes (Table 3). 
Table 3: Virulence genes of P. aeruginosa strains 
Strains Category Function Name 
PA9, PA15, PA16, 
PA28, PA43, PA45, 
PA59, PA120, 
PA132, PA141, 
PA152, PA155 
Quorum sensing Transcriptional activators 
and regulators of the QS 
network. 
(Balasubramanian et al., 
2012; Jimenez et al., 
2012) 
rhlR, luxR 
PA9, PA15, PA16, 
PA28, PA43, PA45, 
PA59, PA120, 
PA141, PA152, 
PA155 
Quorum sensing Transcriptional activators 
and regulators of the QS 
network 
(Balasubramanian et al., 
2012; Jimenez et al., 
2012) 
lasR 
PA9, PA15, PA16, 
PA43, PA45, PA59, 
PA120, PA132, 
PA141, PA152, 
PA155 
Quorum sensing Transcriptional 
regulators of the QS 
network that control the 
production of multiple 
virulence factors 
(Balasubramanian et al., 
2012; Jimenez et al., 
lasI 
22 
 
2012) 
PA9, PA15, PA16, 
PA28, PA43, PA45, 
PA59, PA120, 
PA132, PA141, 
PA152, PA155 
Regulation Most important TCS 
protein in P. aeruginosa 
that is responsible for 
converting an acute 
infection into a chronic 
infection (Coggan & 
Wolfgang, 2012) 
gacA, gacS 
PA9, PA15, PA16, 
PA28, PA43, PA45, 
PA59, PA120, 
PA132, PA141, 
PA152, PA155 
Regulation Result in resistance to 
cationic antimicrobial 
peptides and polymyxin 
B (Balasubramanian et 
al., 2012) 
phoP, phoQ 
PA9, PA15, PA16, 
PA28, PA43, PA45, 
PA59, PA120, 
PA132, PA141, 
PA152, PA155 
Adherence Involved in antimicrobial 
drug resistance due to the 
production of biofilm 
persister cells (Mulcahy 
et al., 2010) 
pilH 
PA9, PA15, PA16, 
PA28, PA43, PA45, 
PA59, PA120, 
PA132, PA141, 
PA152, PA155 
Cell division Results in intrinsic 
resistance to ciproflaxins 
(Breidenstein et al., 
2011) 
ftsK 
PA9, PA15, PA16, 
PA28, PA43, PA45, 
PA59, PA120, 
PA132, PA141, 
PA152, PA155 
Transmembrane 
protein 
transporter 
Results in intrinsic 
resistance to β-lactams 
(Breidenstein et al., 
2011) 
ampG 
PA9, PA15, PA16, 
PA28, PA43, PA45, 
PA59, PA120, 
PA132, PA141, 
PA152, PA155 
Regulation Suppresses regulation of 
the QS virulence genes 
and results in 
overproduction of β-
lactamases and alginate 
(Balasubramanian et al., 
2011) 
ampR β-
lactamase 
regulator 
PA9, PA15, PA16, 
PA28, PA43, PA45, 
PA59, PA120, 
PA132, PA141, 
Efflux pump 
regulation 
Required for acquired 
resistance through 
mutational resistance 
causing efflux pumps 
mexR, nfxB 
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PA152, PA155 MexAB-OprM and 
MexCD-OprJ 
derepression 
(Breidenstein et al., 
2011) 
PA43, PA59, PA120, 
PA 132, PA141 
Secretion 
system 
Type III secretion system 
cytotoxin required for 
full pseudomonal 
virulence and increased 
pathology in the lungs 
(Hauser et al., 1999) 
exoU 
PA9, PA155 Secretion 
system 
Type III secretion system 
toxin required for 
colonization and 
dissemination during 
infection (Lee et al., 
2005) 
exoS 
  
4.2. Antimicrobial Susceptibility Test 
Antibiotic susceptibility for the 18 studied isolates was determined by the Kirby-
Bauer disk agar diffusion method against 12 different antibiotics (Table 4).  
Table 4: Antimicrobial activity of P. aeruginosa tested against antimicrobial agents 
by disk diffusion method (R: Resistant; I: Intermediary Resistant; S: Sensitive) 
 AK ATM CAR CI TE GM 
PA3 S I I R I R 
PA5 R R R R R R 
PA9 R I R R I I 
PA15 R I R R R R 
PA16 R R R R R R 
PA28 R I R R R R 
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PA43 S S I S R S 
PA45 R R R R R R 
PA53 R S R R R R 
PA59 R R R R R R 
PA120 R I R R R R 
PA132 R R R R R R 
PA138 I R R R R R 
PA141 R R R R R R 
PA147 R I R R R R 
PA152 S R R R R R 
PA155 R R R R R R 
PA177 I R R R S R 
       
 IPM CAZ TZP TX TM COL 
PA3 S S S I R S 
PA5 R R S R R S 
PA9 I S R R S S 
PA15 R R R R R S 
PA16 R R R R R S 
PA28 R R R R R S 
PA43 S S S R S S 
PA45 R R R R R S 
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PA53 R R R R R S 
PA59 R R R R R R 
PA120 R R R R R S 
PA132 R R R R R S 
PA138 S R R R R S 
PA141 R R R R R S 
PA147 R R R R R S 
PA152 R R R R R S 
PA155 R R R R R S 
PA177 S R R R R S 
Amikacin (AK), aztreonam (ATM), carbencilin (CAR), ceftazidime (CAZ), 
ceftriaxone (TX), ciproflaxin (CI), colistin (CST), gentamicin (GM), imipenem 
(IPM), piperacillin/tazobactam (TZP), tetracycline (TE) and tobramycin (TM) 
4.2.1. Antibiotic Resistance 
The disk agar diffusion method revealed that 94% of the isolates were resistant to 
ciproflaxin and ceftriaxone, with only 6% being resistant to colistin. Colistin was the 
most effective antimicrobial drug, followed by aztreonam.  The results also showed 
that 33% of the isolates are intermediary resistant to amikacin, and 6% to each of 
ceftriaxone, gentamicin and imipenem (Figure 2). 
Fluoroquinolone resistance (ciprofloxacin) was detected in only one isolate, PA152, 
mediated by the presence of the aac(6')Ib-cr gene (Table 5). The disc diffusion test 
confirmed that PA152 was resistant to fluoroquinolones (ciprofloxacin). The whole 
genome sequencing results (Table 5) were in agreement with the disc diffusion 
results (Table 4). The results of the PCR assays showed that the fluoroquinolone 
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resistant isolates harbored at least two of the mexA, mexC and mexE genes, which 
encode the efflux pumps MexAB-OprM, MexCD-OprJ and MexEF-OprN conferring 
resistance to fluoroquinolone (Table 7). This indicates genotype-phenotype matching 
except for isolate PA43, which was found to be sensitive to ciprofloxacin by the disk 
agar diffusion method while harboring all three mex efflux genes simultaneously 
(Tables 4 and 7).  
The resistant isolates were additionally tested for other antimicrobial agents by the 
disk agar diffusion method, whole-genome sequencing and PCR assays. There was a 
high correlation between the detected phenotypes and genotypes (Tables 4, 5 and 7). 
All isolates (except PA43) were extensively drug-resistant (XDR), being resistant to 
almost all antimicrobial classes (Magiarakos et al., 2011). Isolates PA9, PA15, PA16, 
PA28 and PA45 belonged to the most prevalent sequence type (ST-233) and were 
XDR (Magiarakos et al., 2011), including resistance to aminoglycosides (amikacin, 
gentamycin and tobramycin), fluoroquinolones (ciproflocaxin), β-lactams 
(aztreonam) but susceptible to polymyxin E (colistin). Isolates PA59 and PA132 
belonged to ST-235 and were XDR to the tested aminoglycosides (amikacin, 
gentamycin and tobramycin), monobactams (aztreonam), carbapenems (imipenem), 
penicillins (carbencillin and piperacillin/tazobactam), cephalosporins (ceftazidime 
and ceftriaxone), fluoroquinolones (ciprofloxacin) and tetracyclines, with it being 
additionally resistant to polymyxin E (colistin). 
Among the detected genes were blaPAO and blaOXA-50 genes, which confers additional 
β-lactam/carbapenem resistance. PA152 also harbored blaIMP-15 and blaGES-1 genes, 
involved in hydrolyzing carbapenems. On the other hand, isolates PA9, PA15, PA16, 
PA28 and PA45 carried blaOXA-4 and blaVIM-2, which are linked to carbapenem 
resistance. (Table 5).  
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PCR assays targeting mexA and oprD showed that PA15, PA16 and PA28 carried the 
mexA gene (imipenem resistance), while PA141, PA147 and PA155 carried the oprD 
gene (imipenem resistance). PA45, PA120 and PA132 harbored both mexA and oprD 
(Table 7). However, the remaining imipenem resistant isolates PA5, PA9, PA53 and 
PA152 were negative to all the former genes, with resistance to carbapenems, 
specifically imipenem, being confirmed through the disk agar diffusion assay. 
The aph(3’)-IIb gene, an aminoglycoside-modifying enzyme, was detected in all the 
12 isolates conferring resistance to aminoglycosides (Table 5). The disc diffusion 
assay (Table 4) showed that all the isolates were resistant to at least one of the 
following aminoglycosides: amikacin, gentamicin and tobramycin. Six isolates (PA9, 
PA15, PA16, PA28, PA45 and PA152) carried tetracycline resistant determinants 
tet(A) and tet(G), and phenotypically showed tetracycline resistance (Tables 4 and 5). 
PCR assays revealed that PA43, PA120 and PA132 harbored mexA, which could be 
involved in mediating tetracycline resistance (Table 7). 
Cephalosporin (ceftazidime), extended-spectrum cephalosporins (ceftriaxone), 
penicillin (piperacillin/tazobactam) and polymyxin (colistin) resistance were also 
determined (Table 4). 
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Figure 2. Histogram showing the percentage of resistant, intermediary resistant and 
sensitive isolates to each tested antimicrobial agents. Amikacin (AK), aztreonam 
(ATM), carbencilin (CAR), ceftazidime (CAZ), ceftriaxone (TX), ciproflaxin (CI), 
colistin (CST), gentamicin (GM), imipenem (IPM), piperacillin/tazobactam (TZP), 
tetracycline (TE) and tobramycin (TM)  
Table 5: Antimicrobial resistance determinants of the 12 sequenced P. aeruginosa 
isolates  
Antibiotic Resistance Determinant Isolates 
Aminoglycoside  
aph(3')-Via PA9 
aph(3')-IIb PA9, PA15, PA16, PA28, PA43, PA45, 
PA59, PA120, PA132, PA141, PA152, 
PA155 
aadA2 PA9, PA15, PA16, PA28, PA45 
aadA6 PA59, PA132 
aadA13 PA152 
aac(6')Ib-cr PA152 
aadB PA152 
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strA PA15, PA16, PA28, PA43, PA152 
strB PA15, PA16, PA28, PA43, PA152 
aac(3)-Id PA15, PA16, PA28, PA45 
β-lactam  
BlaPAO PA9, PA15, PA16, PA28, PA43, PA45, 
PA59, PA120, PA132, PA141, PA152, 
PA155 
BlaOXA-50 PA9, PA15, PA16, PA28, PA43, PA45, 
PA59, PA120, PA132, PA141, PA152, 
PA155 
BlaOXA-4 PA9, PA15, PA16, PA28, PA45 
BlaIMP-15 PA152 
BlaGES-1 PA152 
BlaVIM-2 PA15, PA16, PA28, PA45 
Fosfomycin  
fosA PA9, PA15, PA16, PA28, PA43, PA45, 
PA59, PA120, PA132, PA141, PA152, 
PA155 
Phenicol  
catB7 PA9, PA15, PA16, PA28, PA43, PA45, 
PA59, PA120, PA132, PA141, PA152, 
PA155 
cmlA1 PA9, PA15, PA16, PA28, PA45 
Sulphonamide  
sul1 PA9, PA15, PA16, PA28, PA 45, PA59, 
PA132, PA152 
Tetracycline  
tet(A) PA9, PA152 
tet(G) PA9, PA15, PA16, PA28, PA45 
Fluroquinolone  
aac(6')Ib-cr PA152 
Trimethoprim  
dfrB5 PA15, PA16, PA28, PA45 
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4.2.2. Extensive Drug Resistance (XDR) Patterns 
The P. aeruginosa clinical isolates were analyzed for resistance patterns. A total of 
11 patterns were detected among the 18 clinical isolates (Table 6). The most 
common XDR pattern was pattern A (aimkacin, aztreonam, carbencillin, ceftazidime, 
ceftriaxone, cirprofloxacin, gentamicin, imipenem, piperacillin/tazobactam, 
tetracycline and tobramycin), which was detected in five of the isolates: PA16, 
PA45, PA132, PA141 and PA155. It was followed by pattern B (amikacin, 
aztreonam (I), carbencilin, ceftazidime, ceftriaxone, cirproflaxin, gentamicin, 
imipenem, piperacillin/tazobactam, tetracycline and tobramycin) detected in: PA15, 
PA28, PA120 and PA147. All isolates, except PA43, showed resistance against 9-12 
of the tested antibiotics. 
Table 6. Extensive drug resistance patterns of the P. aeruginosa clinical isolates 
against antimicrobial agents 
Pattern XDR Isolate No. of 
Antimicrobial 
Drugs  
Intermediately 
Resistant to 
Antimicrobial 
Drugs 
Resistant to 
Antimicrobial 
Drugs 
Pattern A PA16, PA45, 
PA132, PA141, 
PA155 
11 (R) - AK, ATM, CAR, 
CI, TE, GM, IPM, 
CAZ, TZP, TX, 
TM 
Pattern B PA15, PA28, 
PA120, PA147 
10 (R) 
1 (I)  
ATM AK, CAR, CI, TE, 
GM, IPM, CAZ, 
TZP, TX, TM 
Pattern C PA59 12 (R) - AK, ATM, CAR, 
CI, TE, GM, IPM, 
CAZ, TZP, TX, 
TM, COL 
Pattern D PA3 3 (R) 
4 (I) 
ATM, CAR, 
TE,TX 
CI, GM, TM 
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Pattern E PA5 10 (R) - AK, ATM, CAR, 
CI, TE, GM, IPM, 
CAZ, TX, TM 
Pattern F PA9 5 (R) 
4 (I) 
ATM, TE, GM, 
IPM 
AK, CAR, CI, 
TZP, TX 
Pattern G PA43 2 (R) 
1 (I) 
CAR TE, TX 
Pattern H PA53 10 (R) - AK, CAR, CI, TE, 
GM, IPM, CAZ, 
TZP,TX, TM 
Pattern I PA138 9 (R) 
1 (I) 
AK ATM, CAR, CI, 
TE, GM, IPM,  
CAZ, TZP, TX, 
TM 
Pattern J PA152 10 (R) - ATM, CAR, CI, 
TE, GM, IPM, 
CAZ, T 
Pattern K PA177 8 (R) 
1 (I) 
AK ATM, CAR, CI, 
GM, CAZ, TZP, 
TX, TM 
Amikacin (AK), aztreonam (ATM), carbencilin (CAR), ceftazidime (CAZ), 
ceftriaxone (TX), ciproflaxin (CI), colistin (CST), gentamicin (GM), imipenem 
(IPM), piperacillin/tazobactam (TZP), tetracycline (TE) and tobramycin (TM). 
4.3. Prevalence of Porins, Efflux Pumps and Exotoxin Encoding 
Genes 
PCR assays were performed to detect the presence of three porin encoding genes: 
oprI, oprL and oprD and 3 efflux pumps: mexA, mexC and mexE (amplifying the 
expected 249 bp fragment of the oprI gene, 504 bp fragment of the oprL gene, 1412 
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bp of the oprD gene, 316 bp fragment of mexA gene, 164 bp fragment of the mexC 
gene and 114 bp fragment of mexE gene). The PCR results are shown below (Table 
7). 
PA9, PA15, PA16, PA28 and PA45 belonging to ST-233, were positive for oprI and 
oprL genes, with PA45 being additionally positive for oprD. These isolates also 
harbored the mexA, mexC and mexE genes expect for PA9, which was negative for 
mexA. PA9, PA15 and PA16 were positive for exoS, PA45 carried both exoS and 
exoU, and PA28 was negative for both. 
PA59 and PA132 typed as ST-235 carried the oprI and oprL genes, with PA132 
being also positive for oprD. PA59 and PA132, which were positive for exoU, 
harbored the mexC and mexE genes, and PA132 also carried the mexA gene.  
 
Table 7: PCR products detecting the presence (+) or absence (-) of oprI, oprL, oprD, 
mexA, mexC, mexE, exoS and exoU genes among the 18 P. aeruginosa clinical 
isolates 
Clinical 
Isolates 
Porin Encoding Genes Efflux Pump Encoding 
Genes 
Exotoxin 
Encoding 
Genes 
oprI oprL oprD mexA  mexC  mexE exoS exoU 
PA3 + + + _ + + + _ 
PA5 + + _ _ + + + _ 
PA9 + + _ _ + + + _ 
PA15 + + _ + + + + _ 
PA16 + + _ + + + + _ 
PA28 + + _ + + + _ _ 
PA43 + + _ + + + + + 
PA45 + + + + + + _ _ 
PA53 + + _ _ + + + _ 
PA59 + + _ _ + + _ + 
PA120 + + + + + + _ + 
PA132 + + + + + + _ + 
PA138 + + + _ + + + _ 
PA141 + + + _ + + _ + 
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PA147 + + + _ + + _ + 
PA152 + + _ _ + + + _ 
PA155 + + + _ + + + _ 
PA177 + + + + + + _ + 
 
4.4. Phages and Mobile Elements 
Several phages were identified with the majority of them being classified under the 
phiCTX family of pseudomonal phages (Table 8). Other non-pseudomonal phages 
were also detected such as Escherichia and Stenotrophomonas phages. All phages 
had an average of 42 coding sequences, GC content of 63.52 %, and were 35.8 Kbp 
in length. 
Table 8: Phages detected in the sequenced genomes 
Isolate Phage Name Position No. of CDS Size (Kbp) GC % 
PA9 phiCTX 743077-779746 47 36.6 64.04% 
 YMC11/02/R656 1150747-1182116 34 31.3 64.19% 
PA15 YMC11/02/R656 632693-661109 
 
35 28.4 65.12% 
 phiCTX 5126788-5150819 28 24 60.47% 
 phiCTX 5387820-5399371 16 11.5 65.55% 
 F10 6490102-6565302 102 75.2 60.55% 
PA16 YMC11/02/R656 1496853-1526834 34 29.9 65.80% 
 phiCTX 4920620-4936555 21 15.9 65.78% 
 D3 6397289-6429632 44 32.3 58.30% 
 phiCTX 6590318-6606199 20 15.8 62.35% 
 phiCTX 6808632-6850889 46 42.2 65.48% 
PA28 YMC11/02/R656 1364979-1392112 32 27.1 65.40% 
 phiCTX 5007127-5023794 22 16.6 65.83% 
 F10 6389980-6464497 95 74.5 60.60% 
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 phiCTX 6819795-6862052 46 42.2 65.48% 
PA43 YMC11/02/R656 2118560-2148833 35 30.2 64.48% 
 phiCTX 4341803-4394545 52 52.7 64.43% 
PA45 YMC11/02/R656 989751-1016691 33 26.9 65.44% 
 phiCTX 2381297-2392694 17 11.3 65.71% 
 phiCTX 5556401-5570151 17 13.7 65.69% 
 PMG1 6513133-6547988 46 34.8 58.53% 
 phiCTX 6798804-6839112 41 40.3 64.71% 
PA59 phiCTX 577360-597499 25 20.1 65.25% 
 D3 3192482-3251790 63 59.3 59.88% 
 phiCTX 4139903-4165279 29 25.3 64.70% 
 F10 4885051-4928085 52 43 61.15% 
PA120 YMC11/02/R656 4119126-4149390 34 30.2 64.29% 
 phi297 5648972-5709609 76 60.6 58.55% 
PA132 phiCTX 1815802-1835941 25 20.1 65.25% 
 D3 2451647-2505188 64 53.5 58.95% 
 Bacter_Lily 6646296-6658579 17 12.2 64.43% 
PA141 F10 840623-884601 59 43.9 60.83% 
PA152 phiCTX 119784-163368 51 43.5 63.64% 
 Escher_vB_EcoM_EC
O1230_10 
923732-945394 28 21.6 64.06% 
 phiCTX 1388499-1408769 27 20.2 65.22% 
 PMG1 3782350-3820977 48 38.6 59.71% 
 D3 5283785-5418271 109 134.4 67.38% 
 YMC11/02/R656 5610674-5632005 22 21.3 65.47% 
PA155 Stenot_S1 2935327-2971800 20 36.4 64.53% 
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4.5. Phylogenetic Analysis 
 
Figure 3. Maximum likelihood tree generated using PhyloSift. NCBI was used to 
download the genomes. The maximum likelihood tree was then inferred using 
FigTree including the 12 isolates along with six reference strains: DK2, LESB58, 
M18, NCGM2.S1, PAO1 and UCBPP-PA14. Cellvibrio japonicus Ueda107was 
excluded as an outlier. 
 
A concatenated maximum likelihood tree was generated in order to determine 
epidemiological links between the sequenced isolates. DK2, LESB58, M18, 
NCGM2.S1, PAO1 and UCBPP-PA14 were used as reference genomes. 
Phylogenetic analysis showed the grouping of PA15, PA16, PA28 and PA45 into the 
same clade and in close association with PA9. PA43 was clustered with UCBPP-
PA14 and in close association with PA141, while PA132 was clustered with 
NCGM2.S1 and in close association with PA120. PA155 was in close association 
with PAO1 and LESB58. 
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4.6. Comparative Circular Genomes 
The genome of PA59 was 6,756,856 bp in length, which assembled as a single 
circular chromosome (ANNEX I: circular genomes of all sequenced isolates). The 
sequenced genomes were compared with the reference strain PAO1. 
The results for PA59 additionally revealed 1887 ORFs including: systems for the 
synthesis of amino acids, carbohydrates and cofactors and those required for protein 
metabolism allowing it to grow on minimal media and survive in diverse 
environments. These genes made up 30% of the total ORFs found in P. aeruginosa. 
331 ORFs (5.3%) were shown to be involved in membrane transport, both in terms 
of nutrient uptake through the di- and tri-carboxylates transporters and protein 
secretion through type I-VIII secretion systems. 459 ORFSs (7.3%) were found to be 
involved in regulation and cell signaling, which was significantly higher than what 
was reported in other sequenced bacterial genomes. PA59 also contained 173 ORFs 
(2.7%) encoding members of the RND family of efflux pumps and the MexA-MexB, 
MexC-MexD and MexE-MexF multidrug efflux pumps resulting in increased 
intrinsic resistance to antibiotics. 
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Pseudomonas aeruginosa PA59 
Figure 4. Circular map of P. aerugiosa PA59 genome. Circular representation of the 
PA59 genome; from outside to inside, the tracks display the following information: 
CDSs of PA59 on the forward stand (red), CDSs of PA59 on the reverse stand (blue), 
rRNAs (magenta), tRNAs (brown), GC plot and GC skew with positive value (green) 
and negative value (purple). 
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                                             Pseudomonas aeruginosa PA59 
                                                         (6,756,856 bp) 
Figure 5. Comparative circular map of P. aeruginosa PA59 genome BLASTed 
against the genome of reference strain PAO1. This graphical representation of the 
genome was generated using CGview server V 1.0 (Grant & Stothard, 2008). 
Circular representation of the PA59 genome; from outside to inside, the tracks 
display the following information: clockwise CDSs, anticlockwise CDSs, P. 
aeruginosa PAO1 BLAST comparison, GC content and GC skew. The BLASTN 
alignment tracks displays white regions which indicate parts of the input sequence 
that did not yield a BLAST hit. Regions with a little pink/green color represents parts 
of the input sequence that yield one blast hit. Regions with a dark pink/green color 
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indicate numerous BLAST hits which are commonly attributed to rRNAs or tRNAs. 
Then, GC plot and GC skew with positive value (green) and negative value (purple) 
are shown.  
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Chapter Five
DISCUSSION 
P. aeruginosa is a ubiquitous Gram-negative opportunistic pathogen capable 
of causing a wide range of diseases. In addition to its high rate of prevalence in the 
cystic fibrosis (CF) lung, P. aeruginosa is a frequent cause of acute infections such 
as burns, lung, urinary tract and wound infections (Mulcahy et al., 2014, Wong et al., 
2012). It is involved in the healthcare setting where it poses serious threats to 
immunocompromised patients (Marvig et al., 2013). The increasing frequency of 
extensively drug resistant P. aeruginosa strains has made efficacious antibiotic 
treatment very limited and challenging (Morello et al., 2011). These extensively drug 
resistant strains are resistant to almost all approved antimicrobial agents mainly due 
to overexpression of multiple efflux pumps, production of β-lactamases and loss of 
outer membrane permeability compounded by their ability to form biofilms and 
release toxins (Magiorakos et al., 2011; Castanheira et al., 2014). The increasing 
prevalence of drug resistant and highly pathogenic strains of P. aeruginosa is of 
great concern in Lebanon and various neighbouring countries in the Middle East. 
Accordingly, the genomic features of 12 XDR P. aeruginosa recovered from clinical 
specimens in Lebanon were characterized in this study. 
5.1. Multi Locus Sequence Typing (MLST) 
MLST is a nucleotide sequence-based method used in epidemiological investigations 
targeting antibiotic drug resistant bacteria to understand and elucidate the genetic 
diversity among bacteria (Nunney et al., 2012). This scheme 
discriminates P. aeruginosa isolates by differences in the sequences of seven 
housekeeping genes: acsA, aroE, guaA, mutL, nuoD, ppsA and trpE. Due to 
recombination events in the non-clonal structure of this species, evolution of P. 
aeruginosa has occurred leading to a diversity of serotypes. The analysis of the seven 
loci in this study, demonstrated that the prevalent STs were: ST-233, ST-235, ST-
296, ST-654, ST-1182 and ST-1233, with the most common ST being ST-233 
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(serotype O6; complex D; blaVIM-2). PA15, PA16, PA28 and PA45 belonged to ST-
233, harboured the blaVIM-2 gene (Table 5) and had the same antibiotic resistance 
profile with the exception of aztreonam (PA16 and PA45 were resistant to ATM, 
while PA15 and PA28 were intermediary resistant). PA9 belonged to ST-233 and 
carried another carbapenemase encoding gene, blaOXA-50. This strain belonged to the 
same ST but presented differences in its antibiotic resistance profile. ST-233 was 
first detected in an outbreak in Japan (2006-2009) (Tsutsui et al., 2011). ST-233 
VIM-2 producing P. aeruginosa was detected in one isolate imported from Ghana 
and was imported to Scandinavia (Samuelsen et al., 2009; Zafer et al., 2015). These 
VIM-2 metallo-β-lactamase producing isolates (MBL) were also reported in several 
European countries including Croatia, Greece, Italy, the Netherlands and Turkey and 
in northern Africa including: Algeria and Tunisia and South Africa (Zafer et al., 
2015). The blaVIM-2 gene was more frequent in our study than other MBL encoding 
genes. This was in harmony with the findings of Walsh et al. where the blaVIM-2 gene 
was the most dominant MBL linked to imipenem resistance (Walsh et al., 2008).  
PA59 and PA132 were of sequence type ST-235 (serotype O11; complex B), in 
which aminoglycoside, β-lactam and quinolone resistance was detected with P59 
being additionally colistin resistant (Table 4). ST-235 (predicted founder BG 11) was 
previously detected in different countries (Austria, Belgium, France, Greece, 
Hungary, Italy, Poland, Russia, Serbia, Singapore, Sweden and Turkey), carrying 
different β-lactamases such as: VIM- (Verona-integron-encoded MBL), BEL- 
(Belgium ESBL), IMP- (imipenem), OXA- (active on oxacillin), PAO- (P. 
aeruginosa strain PAO1), PER- (Pseudomonas extended resistance), PSE- 
(Pseudomonas-specific enzyme) and SPM- (São Paulo MBL) (Empel et al., 2007; 
Shevchenko & Edelstein, 2007; Edalucci et al., 2008; Lepsanovic et al., 2008; 
Libisch et al., 2008; Duljasz et al., 2009; Viedma et al., 2009; Glupczynski et al., 
2010). Additionally, both isolates harbored blaOXA-50 and blaPAO genes, coding for 
carbapenemases. 
ST-654 (serotype O11; complex C) is another MDR isolate that was detected in this 
study (PA 152), and characterized by harboring blaPAO, blaOXA-50, blaGES-1 and bla 
IMP-15 genes. ST-654 is an international high-risk clone that was imported from 
Tunisia (Wright et al., 2015; Woodford et al., 2011), and detected in Poland, Sweden 
(carrying blaVIM-2 gene) and the United Kingdom (carrying blaVIM-2 and blaIMP-15) 
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(Mataseje et al., 2016). Pasteran et al. revealed that strains belonging to ST-654 are 
of major importance due to their role in the worldwide dissemination of 
carbapenemases and metallo-β-lactamases (Pasteran et al., 2009).  
5.2. Virulence 
The increased pathogenesis of P. aeruginosa and the high mortality and morbidity 
rates associated with pseudomonal infections are linked to the presence of a 
combination of virulence determinants (Le Berre et al., 2009). The three most potent 
being quorum sensing (QS) components, type III secretion system toxins and two-
component regulatory systems (Hauser, 2011).  
The T3SS is the most significant in P. aeruginosa linked to reduced patient health 
outcome (Berube et al., 2016). Two T3SS effector proteins implicated in virulence, 
ExoS and ExoU, were investigated in this study. Our results revealed that 56% of the 
isolates harbored exoS gene and 39% the exoU, with one isolate having both (PA43) 
and two having none (PA28 and PA45). On the other hand, 50% of the isolates 
carrying exoS were recovered from tracheal aspirate. The fact that all the strains that 
were XDR were either positive for exoU or exoS is very alarming. PA43, however, 
was positive for both exotoxin genes and was resistant to only three out of 12 tested 
antimicrobial agents. However, and contrary to what has been reported previously 
(Adabi et al., 2015; Koutsogiannou et al., 2012; Mitov et al., 2010; El-Solh et al., 
2012; Sawa et al., 2014), PA43 is a unique strain since it carries both exotoxin genes 
and is not XDR. ExoS is capable of disrupting the host, actin cytoskeleton and 
vesicular trafficking, causing host cell death and inhibiting endocytosis (Barbieri et 
al., 2001; Fraylick et al., 2001; Pederson et al., 1998; Rocha et al., 2003). Shaver et 
al. (2004) suggested that clinical strains harboring ExoS show reduced survival and 
increased bacterial spread from the lungs of patients with acute pneumonia. Strains 
carrying ExoU have increased virulence activity and lead to prompt necrotic cell 
death due to its phospholipase ability to damage membranes (Gendrin et al., 2011). 
The results of this study also revealed that 50% of the strains were characterized as 
being exoS+/exoU- and 33% being exoS-/exoU+. Fleiszig et al. showed that exoS+ 
strains are more invasive and can decrease DNA synthesis, while exoU+ strains are 
more cytotoxic and are capable of evading the host immune response. In harmony 
with our results, strains carrying these virulent determinants are of great concern 
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because of their increased potential of causing disease and are consequently treated 
with antimicrobial agents resulting in the emergence of resistance. 
Quorum sensing network systems, las and rhl, are very vital in regulating virulence 
determinants in P. aeruginosa (Moker et al., 2009). Eleven out of the 12 sequenced 
isolates carry the lasI and lasR genes (isolate PA28 lacks lasI and isolate PA132 
lacks lasR) required for virulence. The las system is made up of LasR and LasI (the 
transcriptional activator and auto-inducer synthesis regulator, respectively), which 
induce the expression of a number of target genes and is essential for biofilm 
development. The rhl system is made up of RhlR and RhlI (transcriptional activator 
protein and auto-inducer synthesis regulator, respectively), regulating rhlI and rhlAB 
expression encoding a rhamnosyltransferase needed for rhamnolipids production 
(Jimenez et al., 2012). Rhamnolipids are required for the initial stage of infection 
providing the bacteria with an immune shield, protecting the bacterium from the 
antimicrobial activity of host polymorphonuclear neutrophilic leukocytes (PMNs) 
(Bjarnsholt et al., 2010). The AmpR β-lactamase regulator is another virulence factor 
that has been demonstrated to activate the expression of QS genes (Balasubramanian 
et al., 2012). All sequenced strains carried the AmpR- β-lactamase regulator (Table 
3) and thus, are involved in increased P. aeruginosa virulence and probable 
production of QS linked virulence factors, where AmpR-deficient strains showed 
attenuated virulence (Balasubramanian et al., 2012; Kong et al., 2005). 
In addition to the las QS system, a two-component signal transduction system, 
GacSA, controls biofilm formation and synthesis of several virulence determinants 
(Jimenez et al., 2012). Most importantly, the GacSA system is responsible for 
converting an acute infection into a chronic infection. Upon activation of the GacSA 
system, multiple genes involved in biofilm formation are activated, and many genes 
involved in acute stages of virulence are repressed (Coggan & Wolfgang, 2012). 
gacA and gacS genes were detected in all the sequenced genomes. GacSA system is 
also implicated in antibiotic resistance against ciprofloxacin, tetracyclines and 
tobramycin by controlling rgRsmZ and rgRsmY, two small regulatory RNAs 
(Linares et al., 2009). Our results showed that 10 out of the 12 sequenced isolates 
were resistant to the three antimicrobial classes at the same time and carried both 
gacA and gacS genes. Thus, both the QS and GacSA TCS systems act synergistically 
to enhance the virulence of P. aeruginosa during chronic infections in CF lungs and 
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biofilm formation. The GacSA TCS system also controls T3SS activity. Upon 
phosphorelation of GacA, rgRsmZ and rgRsmY block the negative regulator RNA-
binding protein RsmA, which positively regulates genes of the T3SS. This 
interaction is highly involved in lung injury, to fully augment pseudomonal virulence 
and adaptation (Hauser, 2009).  
Whole-genome sequencing also revealed the presence of phoP and phoQ genes in all 
the 12 sequenced isolates. The phoP-phoQ two-component regulatory system is 
required for resistance to cationic antimicrobial peptides and polymyxin B 
(Balasubramanian et al., 2012) by responding to Mg2+ depleted conditions leading to 
arnB operon overexpression (Lee et al., 2014). The phoP-phoQ two-component 
regulatory system is involved in adaptation to epithelial surfaces, which is very 
important for the pathogenesis of Gram-negative pathogens (Gellatly et al., 2012). 
Although all the sequenced isolates carried phoP and phoQ genes, PA59 was the 
only strain found to be resistant to colistin. Mutations that result in changes in this 
phoP-phoQ two-component regulatory system lead to increased polymyxin E 
(colistin) resistance in P. aeruginosa clinical strains (Lee et al., 2014). Many studies 
have previously reported that colistin-resistant P. aeruginosa strains divert from 
causing an acute to one causing a chronic infection as a result of mutations in the 
phoQ gene (Barrow et al., 2009; Miller et al., 2011; Schurek et al., 2009; Sriramulu 
et al., 2005). According to Gellatlly et al., these mutations along with the added 
pressures of epithelial adherence and polymxin resistance have resulted in the 
increased emergence of MDR and XDR strains. 
5.3. Antibiotic resistance 
A worrying problem is the dissemination of resistant P. aeruginosa strains in 
Lebanon (Al Bayssari et al., 2014; Al Bayssari et al., 2015). The results of our study 
also showed the presence of XDR P. aeruginosa in Lebanese patients upon testing 
against 12 antimicrobial agents. Resistance is most common in the isolates recovered 
from tracheal aspirates All the clinical isolates (except PA43) showed resistance to at 
least nine to 12 of the tested antibiotics, with only one, PA59, being resistant to 
colistin. MDR Gram-negative bacteria have been rapidly spreading in many 
countries worldwide, including Lebanon (Hamouche et al., 2012).  
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One of the most effective treatments against P. aeruginosa infections is the 
carbapenems, followed by fluoroquinolones and aminoglycosides (Morita et al., 
2015). Eight of the 12 sequenced P. aeruginosa isolates were negative for the oprD 
gene as confirmed by the PCR assay (Table 7), which caused the loss of the OprD 
protein and hence explains their resistance to imipenem (Annex I). All 12 isolates 
harbored the ampG gene linked to intrinsic resistance to β-lactams (Breidenstein et 
al., 2011), out of which four (PA15, PA16, PA28 and PA43) carried the mexA gene 
involved in carbapenem resistance. Each of the sequenced isolates also carried at 
least one of the following β-lactamases: blaPAO, blaOXA-50, blaOXA-4, blaIMP-15, blaGES-1 
and/or blaVIM-2. P. aeruginosa has acquired several resistance mechanisms against a 
wide array of antibiotics. P. aeruginosa become resistant to carbapenems through: 
outer membrane porin protein OprD loss or alteration, metallo-β-lactamases (IMP 
and VIM) production and MexA-MexB multidrug efflux pump overexpression (Al 
Bayssari et al., 2014). Carbapenems enter into the periplasmic space of P. 
aeruginosa through the OprD outer membrane porin (Horii et al., 2003; Carmeli et 
al., 1999). Diminished expression or loss of the OprD porin is rather frequent during 
imipenem treatment conferring imipenem resistance, which was similar to what was 
detected in this study. The tripartite system on the other hand, MexA-MexB efflux 
pump, acts synergistically with low outer membrane permeability through loss of 
oprD porin conferring intrinsic multi-drug resistance to P. aeruginosa (PA15, PA16, 
PA28 and PA43) (Poole et al., 2001).  
All types of carbapenemases, except SIM-114 (Seoul imipenemase), have been 
detected in P. aeruginosa isolates around the world. Among them, the MBLs are 
considered as the most clinically important for P. aeruginosa (Walsh et al., 2005). 
MDR and XDR P. aeruginosa are the outcome of a combination of multiple 
mechanisms in a single isolate or the action of a single potent resistance mechanism 
(Tavajjohi et al., 2011). 
 The ability of MBL-producing P. aeruginosa to reach high level endemicity can 
outpace the loss of oprD and up-regulated efflux pumps as leading factors causing 
reduced carbapenem susceptibilitble1y unfolding their potential for causing 
outbreaks (Diab et al., 2013). Our results showed that VIM-2 is the most dominant 
MBL implicated in imipenem resistant P. aeruginosa as supported by results of other 
studies and confers the greatest clinical threat (Walsh et al., 2008, Elias et al., 
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2010). Worldwide, VIM-2 is the dominant MBL gene associated with nosocomial 
outbreaks due to MBL-producing P. aeruginosa. Since MBL-producing isolates can 
cause serious infections that are difficult to treat, their presence in various hospitals 
in Lebanon is of nationwide concern (Al Bayssari et al., 2014). Thus, the combined 
effect of the multiple resistance mechanisms may be the cause of increased 
carbapenem resistance in Lebanon (Al Bayssari et al., 2014, Halat et al., 2017).  
Senda et al. (1996) reported an increasing frequency of MBLs and concluded that 
bacteria producing these enzymes have been responsible for persistent nosocomial 
outbreaks that were accompanied by severe infections (Senda et al., 1996).  
The two main mechanisms of fluoroquinolone resistance in P. aeruginosa include: 
drug target modifications (gyrA, gyrB, parC and parE) and/or multidrug efflux 
pumps (MexA-MexB, MexC-MexD and/or MexE-MexF) overexpression (Llanes et 
al., 2011). Carbapenem-resistant P. aeruginosa infections are best treated with 
fluoroquinolone. This however, led to an increase in the emergence of 
fluoroquinolone resistant strains especially in South Korea resulting in treatment 
failure (Lee et al., 2003). Two isolates, PA59 and PA152 (ST-235; serotype O11; 
complex B), were fluoroquinolone resistant.  Our results also showed that all 12 
sequenced ones harbored the ftsK gene associated with intrinsic resistance to 
ciprofloxacins (Breidenstein et al., 2011), and mexR and nfxB genes linked to 
acquired ciprofloxacin resistance through mutational resistance causing the 
derepression of efflux pumps: MexAB-OprM and MexCD-OprJ (Breidenstein et al., 
2011). In addition, all the 18 isolates carried mexC and mexE (Table 7) and were 
phenotypically resistant to ciprofloxacin (Annex I). Interestingly, PA43 was the only 
strain that was susceptible to ciprofloxacin, while harboring all three mex efflux 
genes simultaneously (Table 7). This could be due to mutations producing non-
functional proteins and the lack of promoters upstream of the site of insertion (Poole 
et al., 2000).  Increased resistance to fluoroquinolones is characterized by the 
simultaneous presence of mexA, mexC and mexE genes (seen in eight out of the 18 
tested isolates) (Adabi et al., 2015). On another note, an interesting characteristic of 
strains expressing efflux-mediated quinolone resistance is their cross-resistance to 
several unrelated antimicrobial agents such as: aminoglycosides, carbapenems, 
penicillins, as a results of the broad substrate specificity of the FQ efflux systems 
47 
 
accommodating a variety of clinically relevant antimicrobial agents in addition to 
FQs (Poole, 2000). 
  
The most widely recognized aminoglycoside resistance mechanism in P. aeruginosa 
is enzymatic alterations of the aminoglycosides via aminoglycoside-
acetyltransferases (AAC), aminoglycoside-adenyltransferases (AAD), and 
aminoglycoside-phosphotransferases (APH). These modifying enzymes spread by 
mobile genetic elements (Teixeira et al., 2016). Two isolates, PA59 and PA132, 
which were typed as ST-235 (serotype O11; complex B), were aminoglycoside 
resistant. This sequence type is associated with aminoglycoside, β-lactam and 
quinolone resistance (Zafer et al., 2015). The most common aminoglycoside-
modifying enzyme detected in this study was the aph(3’)-IIb gene, while aac(6')Ib-cr 
gene was only positive in PA152 (Table 5). Such differences however, could be 
attributed to country-based differences in aminoglycoside usage, with aac(6')Ib-cr 
gene being either the most prevalent or absent ( Kim et al., 2008; Gad et al., 2011; 
Vaziri et al. 2011). The fact that the isolates tested in this study were positive for 
multiple aminoglycoside resistance genes was inconsistent with previous studies 
reporting that the majority of resistant isolates harbor only a single aminoglycoside-
modifying gene (Miller et al., 1997). The synthesis of more than one enzyme 
simultaneously can lead to pan-aminoglycoside resistance (Gad et al., 2011), as seen 
among the isolates in this study with 17 out of the 18 being phenotypically resistant 
to at least one of the following aminoglycosides: amikacin (AK), gentamicin (GM) 
and tobramycin (TM).  
5.4. Phages 
Eight phages were identified in 12 of the sequenced isolates: phiCTX, 
YMC11/02/R656, F10, D3, PMG1, phi297, Bacter_Lily, 
Escher_vB_EcoM_EC01230_10 and Stenot_S1. phiCTX was the most common 
phage detected in this study. phiCTX is dsDNA cytotoxin-converting phage from the 
Myoviridae family that carries the ctx gene and increases virulence potential (Kung 
et al., 2010; Kwan et al., 2006). Battle et al. (2008) showed that P. aeruginosa strains 
harbor the phiCTX phage but lack the ctx gene, due to several deletion and 
recombination events, show attenuated virulence. Four out of 12 of the sequenced 
bacterial genomes (PA16, PA59, PA132 and PA152) carried the D3 bacteriophage, 
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which is known to harbor serotype-converting genes. Thus, these strains are more 
capable of attaching to epithelial cells and evading the human immune response due 
to seroconversion, and thus, more pathogenic (Kung et al., 2010). The F10 
bacteriophage was also detected in four out of the 12 sequenced genomes (PA15, 
PA28, PA59 and PA141). Strains that harbor the F10 bacteriophage have been 
shown to be involved in increased virulence in a rat lung chronic infection model 
(Kwan et al., 2006; Wistanley et al., 2009). 
5.5. Phylogenetic Analysis 
Phylogenetic analysis revealed that the isolates were mainly grouped with the 
reference strains that had a similar sequence type and resistance profiles. PA9, PA15, 
PA16, PA28 and PA45 were grouped into the same clade and in close association 
with PA9 and clustered separately from all the 12 isolates and reference strains used 
in our study. The five isolates were of sequence type ST-233 and were recovered 
from tracheal aspirates or catheter tip (PA9). PA132 and NCGM2.S1 clustered 
together, and had the same ST/clonal complex (ST235 and CC235). PA43 clustered 
with reference strain UCBPP-PA14 but belonged to different STs, and PA132 
clustered with reference strain NCGM2.S1 but also belonged to different STs.  
Overall, our study presented a deep understanding on the multiple resistance 
mechanisms and virulence pathways required for the full potential of P. aeruginosa 
to initiate severe infections. Since novel antimicrobial agents that are FDA approved 
are limited, it is very important to find new approaches to hamper the threat of 
antimicrobial resistance. Such strategies include: targeting regulation of resistance 
mechanisms to enhance antimicrobial drug efficiency and gene expression and 
developing ways to overcome resistance mechanisms. We are aware that a lot is to be 
further studied and discovered regarding how P. aeruginosa regulates its dynamic 
and intricate resistance mechanisms to resist antimicrobial activity. 
5.6. Future Works 
The potential of XDR and cytotoxic P. aeruginosa strains in Lebanon is a great 
threat to public health, especially for immuno-compromised patients. Thus, the 
genotype and phenotype of this important human pathogen must be rapidly 
determined. Drug susceptibility testing and surveillance programs are required to 
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monitor changes in drug resistance patterns and determine the incidence of XDR and 
virulent isolates to limit and prevent outbreaks of pathogenic P. aeruginosa. Once 
the virulent and antibiotic-resistant determinants that cause injury, sepsis and 
mortality are identified, opportunities are available to enhance the clinical outcome 
of the infected patients. Thus, further clinical investigations and suitable protocols 
must be implemented for the proper use of antimicrobial drugs not only to combat 
infections, but also to prevent the spread of P. aeruginosa resistance genes. 
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Chapter Six 
 
CONCLUSION 
 This study showed the emergence of XDR in P. aeruginosa (except isolate 
PA43) against the antimicrobial drugs being routinely used for treatment. 
 The average genome size ranged between 6,579,978-7,009,409 bp, G+C% 
content between 65.90-66.30% and number of contigs 116-396. 
 The isolates belonged to the following sequence types: ST-233, ST-235, ST-
296, ST-654, ST-1182 and ST-1233. 
 Out of the 12 sequenced isolates, 56% of the isolates harboured exoS toxin 
gene and 39% the exoU, with one isolate having both (PA45) and two having 
none (PA28 and PA43). The fact that all the strains that were XDR were 
either positive for exoU or exoS is very alarming. 
 PA45 is a unique strain in this study since it lacks both exotoxin genes but is 
XDR at the same time. 
 Other virulence determinants present included: lasI, lasR, ampR β-lactamase 
regulator, gacS, gacA, phoP and phoQ. 
 Although all the sequenced isolates carried phoP and phoQ genes (which 
confer resistance to polymyxin B, PA59 was the only strain found to be 
resistant to colistin which may be due to haboring a mutated phoQ gene. 
 Out of the 12 sequenced isolates, 67% were negative for the oprD gene, 
100% were positive for the ampG gene, 33% were positive for the mexA 
gene all of which confer carbapenem resistance. 
 A large variety of the β-lactamase genes (blaPAO, blaOXA-50, blaOXA-4, blaIMP-15, 
blaGES-1 and/or blaVIM-2 genes) were detected in all the sequenced strains 
conferring carbapenem resistance. 
 Our results showed that VIM-2 is the most dominant MBL implicated in 
imipenem resistant P. aeruginosa as supported by results of other studies and 
confers the greatest clinical threat. 
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 All sequenced isolates isolates harbored the ftsK gene, mexR and nfxB genes 
which are linked to fluoroquinolone resistance. In addition, all the 18 isolates 
carried mexC and mexE and were phenotypically resistant to ciprofloxacin. 
 PA43 was the only strain that was susceptible to ciprofloxacin while 
harboring all three mex efflux genes simultaneously. This could be due to 
mutations producing non-functional proteins and the lack of promoters 
upstream of the site of insertion. 
 In this study, P. aeruginosa isolates contained multiple aminoglycoside 
resistance genes, which is inconsistent with previous studies reporting that the 
majority of resistant isolates harbor only a single aminoglycoside-modifying 
gene 
 The most frequent aminoglycoside-modifying enzyme detected in this study 
was the aph(3’)-IIb gene conferring aminoglycoside resistance. 
 PA43 carried three aminoglycoside resistance encoding genes but was still 
susceptible to the aminoglycosides tested. The exact reason for the sensitive 
phenotype of this strain is unknown. 
 Eight plasmids were identified: phiCTX, YMC11/02/R656, F10, D3, PMG1, 
phi297, Bacter_Lily, Escher_vB_EcoM_EC01230_10 and Stenot_S1. 
phiCTX was the most common detected plasmid in this study, followed by 
YMC11/02/R656. 
 Drug susceptibility testing and surveillance programs are required to monitor 
changes in drug resistance patterns and determine the incidence of XDR and 
virulent isolates to limit and prevent outbreaks of pathogenic P. aeruginosa. 
 Further clinical investigations and suitable protocols must be implemented for 
the proper use of antimicrobial drugs not only to combat infections, but also 
to prevent the spread of P. aeruginosa resistance genes. 
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ANNEX I 
6.1. Circular Images 
 
 
Pseudomonas aeruginosa PA9 
Figure 1. Circular map of P. aeruginosa PA9 genome. Circular representation of the 
PA59 genome; from outside to inside, the tracks display the following information: 
CDSs of PA59 on the forward stand (red), CDSs of PA59 on the reverse stand (blue), 
rRNAs (prurple), tRNAs (green), GC plot and GC skew with above mean value 
(grey) and below mean value (black). 
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Pseudomonas aeruginosa PA15 
Figure 2. Circular map of P. aeruginosa PA15 genome. Circular representation of 
the PA59 genome; from outside to inside, the tracks display the following 
information: CDSs of PA59 on the forward stand (red), CDSs of PA59 on the reverse 
stand (blue), rRNAs (prurple), tRNAs (green), GC plot and GC skew with above 
mean value (grey) and below mean value (black). 
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Pseudomonas aeruginosa PA16 
Figure 3. Circular map of P. aeruginosa PA16 genome. Circular representation of 
the PA59 genome; from outside to inside, the tracks display the following 
information: CDSs of PA59 on the forward stand (red), CDSs of PA59 on the reverse 
stand (blue), rRNAs (prurple), tRNAs (green), GC plot and GC skew with above 
mean value (grey) and below mean value (black). 
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Pseudomonas aeruginosa PA28 
Figure 4. Circular map of P. aeruginosa PA28 genome. Circular representation of 
the PA59 genome; from outside to inside, the tracks display the following 
information: CDSs of PA59 on the forward stand (red), CDSs of PA59 on the reverse 
stand (blue), rRNAs (prurple), tRNAs (green), GC plot and GC skew with above 
mean value (grey) and below mean value (black). 
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Pseudomonas aeruginosa PA43 
Figure 5. Circular map of P. aeruginosa PA43 genome. Circular representation of 
the PA59 genome; from outside to inside, the tracks display the following 
information: CDSs of PA59 on the forward stand (red), CDSs of PA59 on the reverse 
stand (blue), rRNAs (prurple), tRNAs (green), GC plot and GC skew with above 
mean value (grey) and below mean value (black). 
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Pseudomonas aeruginosa PA45 
Figure 6. Circular map of P. aeruginosa PA45 genome. Circular representation of 
the PA59 genome; from outside to inside, the tracks display the following 
information: CDSs of PA59 on the forward stand (red), CDSs of PA59 on the reverse 
stand (blue), rRNAs (prurple), tRNAs (green), GC plot and GC skew with above 
mean value (grey) and below mean value (black). 
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Pseudomonas aeruginosa PA53 
Figure 7. Circular map of P. aeruginosa PA53 genome. Circular representation of 
the PA59 genome; from outside to inside, the tracks display the following 
information: CDSs of PA59 on the forward stand (red), CDSs of PA59 on the reverse 
stand (blue), rRNAs (prurple), tRNAs (green), GC plot and GC skew with above 
mean value (grey) and below mean value (black). 
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Pseudomonas aeruginosa PA120 
Figure 8. Circular map of P. aeruginosa PA120 genome. Circular representation of 
the PA59 genome; from outside to inside, the tracks display the following 
information: CDSs of PA59 on the forward stand (red), CDSs of PA59 on the reverse 
stand (blue), rRNAs (prurple), tRNAs (green), GC plot and GC skew with above 
mean value (grey) and below mean value (black). 
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Pseudomonas aeruginosa PA132 
Figure 9. Circular map of P. aeruginosa PA132 genome. Circular representation of 
the PA59 genome; from outside to inside, the tracks display the following 
information: CDSs of PA59 on the forward stand (red), CDSs of PA59 on the reverse 
stand (blue), rRNAs (prurple), tRNAs (green), GC plot and GC skew with above 
mean value (grey) and below mean value (black). 
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Pseudomonas aeruginosa PA141 
Figure 10. Circular map of P. aeruginosa PA141 genome. Circular representation of 
the PA59 genome; from outside to inside, the tracks display the following 
information: CDSs of PA59 on the forward stand (red), CDSs of PA59 on the reverse 
stand (blue), rRNAs (magenta), tRNAs (brown), GC plot and GC skew with positive 
value (green) and negative value (purple). 
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Pseudomonas aeruginosa PA59 
Figure 11. Circular map of P. aeruginosa PA152 genome. Circular representation of 
the PA59 genome; from outside to inside, the tracks display the following 
information: CDSs of PA59 on the forward stand (red), CDSs of PA59 on the reverse 
stand (blue), rRNAs (magenta), tRNAs (brown), GC plot and GC skew with positive 
value (green) and negative value (purple). 
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Pseudomonas aeruginosa PA155 
Figure 12. Circular map of P. aeruginosa PA155 genome. Circular representation of 
the PA59 genome; from outside to inside, the tracks display the following 
information: CDSs of PA59 on the forward stand (red), CDSs of PA59 on the reverse 
stand (blue), rRNAs (magenta), tRNAs (brown), GC plot and GC skew with positive 
value (green) and negative value (purple). 
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Pseudomonas aeruginosa PA9 
Figure 13. Comparative circular map of P. aeruginosa PA9 genome BLASTed 
against the genome of reference strain PAO1. This graphical representation of the 
genome was generated using CGview server V 1.0 (Grant & Stothard, 2008). 
Circular representation of the PA59 genome; from outside to inside, the tracks 
display the following information: clockwise CDSs, anticlockwise CDSs, P. 
aeruginosa PAO1 BLAST comparison, GC content and GC skew. The BLASTN 
alignment tracks displays white regions which indicate parts of the input sequence 
that did not yield a BLAST hit. Regions with a little pink/green color represents parts 
of the input sequence that yield one blast hit. Regions with a dark pink/green color 
indicate numerous BLAST hits which are commonly attributed to rRNAs or tRNAs. 
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Then, GC plot and GC skew with positive value (green) and negative value (purple) 
are shown.  
 
 
 
Pseudomonas aeruginosa PA15 
Figure 14. Comparative circular map of P. aeruginosa PA15 genome BLASTed 
against the genome of reference strain PAO1. This graphical representation of the 
genome was generated using CGview server V 1.0 (Grant & Stothard, 2008). 
Circular representation of the PA59 genome; from outside to inside, the tracks 
display the following information: clockwise CDSs, anticlockwise CDSs, P. 
aeruginosa PAO1 BLAST comparison, GC content and GC skew. The BLASTN 
alignment tracks displays white regions which indicate parts of the input sequence 
that did not yield a BLAST hit. Regions with a little pink/green color represents parts 
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of the input sequence that yield one blast hit. Regions with a dark pink/green color 
indicate numerous BLAST hits which are commonly attributed to rRNAs or tRNAs. 
Then, GC plot and GC skew with positive value (green) and negative value (purple) 
are shown.  
 
 
 
Pseudomonas aeruginosa PA16 
Figure 15. Comparative circular map of P. aeruginosa PA16 genome BLASTed 
against the genome of reference strain PAO1. This graphical representation of the 
genome was generated using CGview server V 1.0 (Grant & Stothard, 2008). 
Circular representation of the PA59 genome; from outside to inside, the tracks 
display the following information: clockwise CDSs, anticlockwise CDSs, P. 
aeruginosa PAO1 BLAST comparison, GC content and GC skew. The BLASTN 
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alignment tracks displays white regions which indicate parts of the input sequence 
that did not yield a BLAST hit. Regions with a little pink/green color represents parts 
of the input sequence that yield one blast hit. Regions with a dark pink/green color 
indicate numerous BLAST hits which are commonly attributed to rRNAs or tRNAs. 
Then, GC plot and GC skew with positive value (green) and negative value (purple) 
are shown.  
 
 
 
Pseudomonas aeruginosa PA28 
 
Figure 16. Comparative circular map of P. aeruginosa PA28 genome BLASTed 
against the genome of reference strain PAO1. This graphical representation of the 
genome was generated using CGview server V 1.0 (Grant & Stothard, 2008). 
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Circular representation of the PA59 genome; from outside to inside, the tracks 
display the following information: clockwise CDSs, anticlockwise CDSs, P. 
aeruginosa PAO1 BLAST comparison, GC content and GC skew. The BLASTN 
alignment tracks displays white regions which indicate parts of the input sequence 
that did not yield a BLAST hit. Regions with a little pink/green color represents parts 
of the input sequence that yield one blast hit. Regions with a dark pink/green color 
indicate numerous BLAST hits which are commonly attributed to rRNAs or tRNAs. 
Then, GC plot and GC skew with positive value (green) and negative value (purple) 
are shown.  
 
 
 
Pseudomonas aeruginosa PA43 
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Figure 17. Comparative circular map of P. aeruginosa PA43 genome BLASTed 
against the genome of reference strain PAO1. This graphical representation of the 
genome was generated using CGview server V 1.0 (Grant & Stothard, 2008). 
Circular representation of the PA59 genome; from outside to inside, the tracks 
display the following information: clockwise CDSs, anticlockwise CDSs, P. 
aeruginosa PAO1 BLAST comparison, GC content and GC skew. The BLASTN 
alignment tracks displays white regions which indicate parts of the input sequence 
that did not yield a BLAST hit. Regions with a little pink/green color represents parts 
of the input sequence that yield one blast hit. Regions with a dark pink/green color 
indicate numerous BLAST hits which are commonly attributed to rRNAs or tRNAs. 
Then, GC plot and GC skew with positive value (green) and negative value (purple) 
are shown. 
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Pseudomonas aeruginosa PA45 
Figure 18. Comparative circular map of P. aeruginosa PA45 genome BLASTed 
against the genome of reference strain PAO1. This graphical representation of the 
genome was generated using CGview server V 1.0 (Grant & Stothard, 2008). 
Circular representation of the PA59 genome; from outside to inside, the tracks 
display the following information: clockwise CDSs, anticlockwise CDSs, P. 
aeruginosa PAO1 BLAST comparison, GC content and GC skew. The BLASTN 
alignment tracks displays white regions which indicate parts of the input sequence 
that did not yield a BLAST hit. Regions with a little pink/green color represents parts 
of the input sequence that yield one blast hit. Regions with a dark pink/green color 
indicate numerous BLAST hits which are commonly attributed to rRNAs or tRNAs. 
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Then, GC plot and GC skew with positive value (green) and negative value (purple) 
are shown. 
 
 
 
Pseudomonas aeruginosa PA120 
Figure 19. Comparative circular map of P. aeruginosa PA120 genome BLASTed 
against the genome of reference strain PAO1. This graphical representation of the 
genome was generated using CGview server V 1.0 (Grant & Stothard, 2008). 
Circular representation of the PA59 genome; from outside to inside, the tracks 
display the following information: clockwise CDSs, anticlockwise CDSs, P. 
aeruginosa PAO1 BLAST comparison, GC content and GC skew. The BLASTN 
alignment tracks displays white regions which indicate parts of the input sequence 
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that did not yield a BLAST hit. Regions with a little pink/green color represents parts 
of the input sequence that yield one blast hit. Regions with a dark pink/green color 
indicate numerous BLAST hits which are commonly attributed to rRNAs or tRNAs. 
Then, GC plot and GC skew with positive value (green) and negative value (purple) 
are shown.  
 
 
Pseudomonas aeruginosa PA132 
Figure 20. Comparative circular map of P. aeruginosa PA132 genome BLASTed 
against the genome of reference strain PAO1. This graphical representation of the 
genome was generated using CGview server V 1.0 (Grant & Stothard, 2008). 
Circular representation of the PA59 genome; from outside to inside, the tracks 
display the following information: clockwise CDSs, anticlockwise CDSs, P. 
aeruginosa PAO1 BLAST comparison, GC content and GC skew. The BLASTN 
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alignment tracks displays white regions which indicate parts of the input sequence 
that did not yield a BLAST hit. Regions with a little pink/green color represents parts 
of the input sequence that yield one blast hit. Regions with a dark pink/green color 
indicate numerous BLAST hits which are commonly attributed to rRNAs or tRNAs. 
Then, GC plot and GC skew with positive value (green) and negative value (purple) 
are shown.  
 
 
Pseudomonas aeruginosa PA152 
Figure 21. Comparative circular map of P. aeruginosa PA152 genome BLASTed 
against the genome of reference strain PAO1. This graphical representation of the 
genome was generated using CGview server V 1.0 (Grant & Stothard, 2008). 
Circular representation of the PA59 genome; from outside to inside, the tracks 
display the following information: clockwise CDSs, anticlockwise CDSs, P. 
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aeruginosa PAO1 BLAST comparison, GC content and GC skew. The BLASTN 
alignment tracks displays white regions which indicate parts of the input sequence 
that did not yield a BLAST hit. Regions with a little pink/green color represents parts 
of the input sequence that yield one blast hit. Regions with a dark pink/green color 
indicate numerous BLAST hits which are commonly attributed to rRNAs or tRNAs. 
Then, GC plot and GC skew with positive value (green) and negative value (purple) 
are shown.  
 
 
 
Pseudomonas aeruginosa PA155 
Figure 22. Comparative circular map of P. aeruginosa PA155 genome BLASTed 
against the genome of reference strain PAO1. This graphical representation of the 
genome was generated using CGview server V 1.0 (Grant & Stothard, 2008). 
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Circular representation of the PA59 genome; from outside to inside, the tracks 
display the following information: clockwise CDSs, anticlockwise CDSs, P. 
aeruginosa PAO1 BLAST comparison, GC content and GC skew. The BLASTN 
alignment tracks displays white regions which indicate parts of the input sequence 
that did not yield a BLAST hit. Regions with a little pink/green color represents parts 
of the input sequence that yield one blast hit. Regions with a dark pink/green color 
indicate numerous BLAST hits which are commonly attributed to rRNAs or tRNAs. 
Then, GC plot and GC skew with positive value (green) and negative value (purple) 
are shown.  
 
